QuidelOrtho 10-K 19 Feb 21 2020 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Dec. 31, 2020	Feb. 05, 2021	Jun. 30, 2020
Cover [Abstract]
Title of 12(b) Security	Common stock, $0.001 par value
Entity Incorporation, State or Country Code	DE
Document Transition Report	false
Document Quarterly Report	true
Entity Registrant Name	QUIDEL CORP /DE/
Entity Central Index Key	0000353569
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Trading Symbol	QDEL
ICFR Auditor Attestation Flag	true
Amendment Flag	false
Entity Common Stock, Shares Outstanding		42,319,115
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Public Float			$ 8,173,089,184
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Tax Identification Number	94-2573850
Entity Address, Postal Zip Code	92121
Security Exchange Name	NASDAQ
Entity File Number	0-10961
Documents Incorporated by Reference	(To the Extent Indicated Herein)
City Area Code	858
Local Phone Number	552-1100
Entity Address, Address Line One	9975 Summers Ridge Road
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 489,941	$ 52,775
Accounts receivable, net	497,688	94,496
Inventories	113,798	58,086
Prepaid expenses and other current assets	40,975	16,870
Total current assets	1,142,402	222,227
Property, plant and equipment, net	110,481	79,762
Right-of-use assets	100,544	92,119
Goodwill	337,032	337,018
Intangible assets, net	122,431	148,112
Deferred tax asset	44,762	24,502
Other non-current assets	13,512	7,127
Total assets	1,871,164	910,867
Current liabilities:
Accounts payable	86,316	26,701
Accrued payroll and related expenses	34,781	17,286
Accrued Income Taxes, Current	127,788	0
Operating Lease, Liability, Current	7,799	6,412
Contingent consideration	5,987	5,969
Deferred consideration	42,000	42,000
Convertible Senior Notes	0	12,661
Other current liabilities	32,290	14,862
Total current liabilities	336,961	125,891
Operating lease liabilities - non-current	100,706	93,227
Deferred consideration - non-current	73,951	109,382
Contingent consideration - non-current	5,909	10,566
Other non-current liabilities	20,934	11,981
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $.001 par value per share; 5,000 shares authorized; none issued or outstanding at December 31, 2020 and 2019	0	0
Common stock, $.001 par value per share; 97,500 shares authorized; 42,290 and 41,868 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively	42	42
Additional paid-in capital	388,121	425,557
Accumulated other comprehensive loss	(431)	(463)
Retained earnings	944,971	134,684
Total stockholders’ equity	1,332,703	559,820
Total liabilities and stockholders’ equity	$ 1,871,164	$ 910,867

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	97,500,000	97,500,000
Common stock, shares issued	42,290,000	41,868,000
Common stock, shares outstanding	42,290,000	41,868,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 1,661,668	$ 534,890	$ 522,285
Cost of Goods and Services Sold	312,813	214,085	206,572
Gross profit	1,348,855	320,805	315,713
Research and development	84,292	52,553	51,649
Sales and marketing	133,957	111,114	108,987
General and administrative	66,586	52,755	44,951
Acquisition and integration costs	3,694	11,667	14,197
Total operating expenses	288,529	228,089	219,784
Operating income	1,060,326	92,716	95,929
Other expense, net	(9,623)	(14,790)	(24,283)
Loss on extinguishment of debt	(10,384)	(748)	(8,262)
Total other expense, net	(20,007)	(15,538)	(32,545)
Income before income taxes	1,040,319	77,178	63,384
Provision (benefit) for income taxes	230,032	4,257	(10,799)
Net income	$ 810,287	$ 72,921	$ 74,183
Basic earnings per share	$ 19.24	$ 1.78	$ 1.95
Diluted earnings per share	$ 18.60	$ 1.73	$ 1.86
Shares used in basic per share calculation	42,124	40,860	37,995
Shares used in diluted per share calculation	43,591	43,111	42,554

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statement of Comprehensive Income [Abstract]
Net income	$ 810,287	$ 72,921	$ 74,183
Other comprehensive income (loss)
Changes in cumulative translation adjustment, net of tax	2,554	(322)	(139)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	(2,993)	716	0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	471	(718)	0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax	(2,522)	(2)	0
Comprehensive income	$ 810,319	$ 72,597	$ 74,044

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional paid-in capital [Member]	Accumulated other comprehensive income (loss) [Member]	Retained earnings [Member]	Convertible Debt
Beginning Balance at Dec. 31, 2017	$ 227,104	$ 35	$ 239,489	$ 0	$ (12,420)
Beginning Balance, shares at Dec. 31, 2017		34,540,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under equity compensation plans	17,047	$ 0	17,047
Issuance of common stock under equity compensation plans, shares		1,237,000
Stock-based compensation expense	10,078		10,078
Repurchases of common stock	(4,344)	$ 0	(4,344)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax	0
Repurchase of common stock, shares		(90,000)
Changes in cumulative translation adjustment, net of tax	(139)			(139)
Issuance of shares in exchange for Convertible Senior Notes	200,219	$ 4	200,215
Number of shares of common stock issued						3,699,000
Tax impact from the conversion of Convertible Senior Notes	2,162		2,162
Reduction for equity component of Convertible Senior Notes exchanged	(100,726)		(100,726)
Net income	74,183				74,183
Ending Balance at Dec. 31, 2018	425,584	$ 39	363,921	(139)	61,763
Ending Balance, shares at Dec. 31, 2018		39,386,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under equity compensation plans	16,799	$ 2	16,797
Issuance of common stock under equity compensation plans, shares		1,152,000
Stock-based compensation expense	12,088		12,088
Repurchases of common stock	(10,728)	$ 0	(10,728)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(324)			(324)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax	(2)
Repurchase of common stock, shares		(167,000)
Changes in cumulative translation adjustment, net of tax	(322)
Issuance of shares in exchange for Convertible Senior Notes	86,428	$ 1	86,427
Number of shares of common stock issued						1,497,000
Tax impact from the conversion of Convertible Senior Notes	568		568
Reduction for equity component of Convertible Senior Notes exchanged	(43,516)		(43,516)
Net income	72,921				72,921
Ending Balance at Dec. 31, 2019	559,820	$ 42	425,557	(463)	134,684
Ending Balance, shares at Dec. 31, 2019		41,868,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under equity compensation plans	10,380	$ 0	10,380
Issuance of common stock under equity compensation plans, shares		490,000
Stock-based compensation expense	18,969		18,969
Repurchases of common stock	(47,889)	$ 0	(47,889)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	32			32
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax	$ (2,522)
Repurchase of common stock, shares	(257,329)	(294,000)
Changes in cumulative translation adjustment, net of tax	$ 2,554
Issuance of shares in exchange for Convertible Senior Notes	7,230	$ 0	7,230
Number of shares of common stock issued						225,955
Tax impact from the conversion of Convertible Senior Notes	54		54
Reduction for equity component of Convertible Senior Notes exchanged	26,180
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments			26,180
Net income	810,287				810,287
Ending Balance at Dec. 31, 2020	$ 1,332,703	$ 42	$ 388,121	$ (431)	$ 944,971
Ending Balance, shares at Dec. 31, 2020		42,290,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
OPERATING ACTIVITIES
Net income	$ 810,287	$ 72,921	$ 74,183
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, amortization and other	49,089	47,827	46,266
Stock-based compensation expense	21,019	13,252	11,709
Impairment loss	0	1,481	0
Amortization of debt discount and deferred issuance costs	771	1,582	3,952
Change in fair value of acquisition contingencies	1,405	1,467	1,114
Accretion of interest on deferred consideration	6,569	8,224	10,000
Amortization of inventory step-up to fair value	0	0	3,650
Net change in operating lease right-of-use assets and liabilities	434	3,964	0
Right-of-use assets	100,544	92,119
Change in deferred tax assets and liabilities	(20,211)	(1,742)	(20,458)
Change in fair value of derivative liabilities - Convertible Senior Notes	1,084	0	0
Loss on extinguishment of debt	10,384	748	8,262
Increase (Decrease) in Operating Capital
Accounts receivable	(402,094)	(36,059)	8,236
Inventories	(54,903)	9,143	(3,974)
Prepaid expenses and other current and non-current assets	(14,264)	4,314	(12,681)
Accounts payable	52,226	2,434	(331)
Accrued payroll and related expenses	16,024	(1,037)	1,674
Increase (Decrease) in Income Taxes Payable	137,708	4,175	2,082
Other current and non-current liabilities	14,235	1,791	2,661
Net cash provided by operating activities	629,763	134,485	136,345
INVESTING ACTIVITIES
Acquisitions of property, equipment and intangibles	(64,927)	(27,229)	(31,689)
Proceeds from government assistance allocated to fixed assets	1,605	0	0
Proceeds from sale of Summers Ridge Property	0	0	146,644
Net cash (used for) provided by investing activities	(63,322)	(27,229)	114,955
FINANCING ACTIVITIES
Proceeds from issuance of common stock	9,613	14,782	17,047
Payments of debt issuance costs	0	0	(513)
Payments on finance lease obligation	(511)	(371)	(130)
Payments on Revolving Credit Facility	0	(53,188)	(40,000)
Repurchases of common stock	(47,889)	(10,728)	(4,344)
Payments on acquisition contingent consideration	(6,044)	(4,044)	(6,303)
Payments of deferred consideration	(42,000)	(44,000)	(46,000)
Payment on Convertible Senior Note and Derivative Liability	(43,446)	0	0
Payments of Term Loan	0	0	(161,813)
Transaction costs related to debt exchange	0	(733)	(2,002)
Net cash used for financing activities	(130,277)	(98,282)	(244,058)
Effect of exchange rate changes on cash	1,002	106	367
Net increase in cash and cash equivalents	437,166	9,080	7,609
Cash and cash equivalents, beginning of period	52,775	43,695	36,086
Cash and cash equivalents, at end of period	489,941	52,775	43,695
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid during the period for interest	480	2,295	7,929
Cash paid during the period for income taxes	109,912	2,189	6,923
Purchase of property, equipment and intangibles by incurring current liabilities	7,160	1,040	1,785
Accrued receivable for capital expenditures to be reimbursed under a government contract	15,854
Reduction of other current liabilities upon issuance of restricted share units	767	2,018	0
Extinguishment of Convertible Senior Notes through issuance of stock	7,230	86,428	200,219
Principal amount of Term Loan exchanged for Revolving Credit Facility	$ 0	$ 0	$ 83,187

Company Operations and Summary

Company Operations and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Company Operations and Summary of Significant Accounting Policies	Company Operations and Summary of Significant Accounting Policies Quidel Corporation (the “Company”) commenced operations in 1979. The Company operates in one business segment, which develops, manufactures and markets diagnostic testing solutions. These diagnostic tests can be categorized in the following product categories: Rapid Immunoassay, Cardiometabolic Immunoassay, Specialized Diagnostic Solutions and Molecular Diagnostic Solutions. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics and wellness screening centers. The Company markets its products through a network of distributors and a direct sales force. The accompanying consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with generally accepted accounting principles in the U.S. Consolidation— The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. Cash and Cash Equivalents— The Company considers cash equivalents to be highly liquid investments with a maturity at the date of purchase of three months or less. The Company invests its cash equivalents primarily in money market funds with high quality institutions. Accounts Receivable— The Company sells its products directly to hospitals and reference laboratories as well as to distributors in the U.S. and internationally (see Note 9). The Company periodically assesses the financial strength of these customers and establishes reserves for anticipated losses when necessary, which historically have not been material. The balance of accounts receivable is net of reserves of $103.4 million and $16.0 million at December 31, 2020 and 2019, respectively, of which the reserve related to contract rebates was $100.8 million and $15.7 million, respectively. Concentration of Credit Risk— Financial instruments that potentially subject the Company to significant concentrations of credit risk consists principally of trade accounts receivable and cash equivalents. The Company performs credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary, but generally requires no collateral. Credit quality is monitored regularly by reviewing credit history. The Company believes that the concentration of credit risk in its trade accounts receivables is moderated by its credit evaluation process, relatively short collection terms, the high level of credit worthiness of its customers, and letters of credit issued on the Company’s behalf. Potential credit losses are limited to the gross value of accounts receivable. Inventories— Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. The Company reviews the components of its inventory periodically for excess, obsolete and impaired inventory and records a reduction to the carrying value when identified. Property, Plant and Equipment— Property, plant and equipment is recorded at cost and depreciated over the estimated useful lives of the assets ( three Goodwill and Intangible Assets— Intangible assets are recorded at cost and amortized on a straight-line basis over their estimated useful lives, except for indefinite-lived intangibles such as goodwill. Software development costs associated with software to be leased or otherwise marketed are expensed as incurred until technological feasibility has been established. After technological feasibility is established, software development costs are capitalized and amortized on a straight-line basis over the estimated product life. Convertible Debt— The Company accounts for convertible debt instruments that may be settled in cash upon conversion (including combination settlement of cash equal to the “principal portion” and delivery of the “share amount” in excess of the conversion value over the principal portion in shares of common stock and/or cash) by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate. The Company determines the carrying amount of the liability component by measuring the fair value of similar debt instruments that do not have the conversion feature. If no similar debt instrument exists, the Company estimates fair value by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities. Determining the fair value of the debt component requires the use of accounting estimates and assumptions. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense. See Note 3 for additional discussion of the Convertible Senior Notes issued in December 2014. Revenue Recognition— The Company records revenues primarily from product sales. These revenues are recorded net of rebates and other discounts. These rebates and discounts are estimated at the time of sale, and are largely driven by various customer program offerings, including special pricing agreements, promotions and other volume-based incentives. Rebates and discounts are calculated based upon historical experience, estimated discounting levels and estimated distributor inventory balances and recorded as a reduction of sales with offsets to accounts receivable and other current liabilities, respectively. Revenue is recognized when control of the products is transferred to the customers in an amount that reflects the consideration the Company expects to receive from the customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract and the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. A performance obligation is considered to be satisfied once the control of a product is transferred to the customer or the service is provided to the customer, meaning the customer has the ability to use and obtain the benefit of the goods or service. A portion of product sales includes revenues for diagnostic kits, which are utilized on leased instrument systems under the Company’s “reagent rental” program. The reagent rental program provides customers the right to use the instruments at no separate cost to the customer in consideration for a multi-year agreement to purchase annual minimum amounts of consumables (“reagents” or “diagnostic kits”). When an instrument is placed with a customer under a reagent rental agreement, the Company retains title to the equipment and it remains capitalized on the Company’s Consolidated Balance Sheets as property, plant and equipment, net. The instrument is depreciated on a straight-line basis over the lesser of the lease term or life of the instrument. Depreciation expense is recorded in cost of sales included in the Consolidated Statements of Income. Instrument and consumables under the reagent rental agreements are deemed two distinct performance obligations. Though the instrument and consumables do not have any use to customers without one another, they are not highly interdependent because they do not significantly affect each other. The Company would be able to fulfill its promise to transfer the instrument even if its customers did not purchase any consumables and the Company would be able to fulfill its promise to provide the consumables even if customers acquired instruments separately . The contract price is allocated between these two performance obligations based on the relative standalone selling prices. The instrument is considered an operating lease and revenue allocated to the instrument will be separately disclosed, if material. Government Assistance — During the year ended December 31, 2020, the Company entered into a contract with the National Institute of Health (“NIH”), through its newly launched Rapid Acceleration of Diagnostics - Advanced Technology Platforms initiative, to support the Company’s expansion of its manufacturing capacity for its diagnostic assays that test for the SARS-CoV-2 antigen. The contract provides for consideration to the Company of up to $65.0 million and has a performance period of one year, which began in July 2020. The contract includes key deliverables and milestones that will directly support the upgrade and addition of new manufacturing lines as well as the outfitting of a new distribution center. The Company will also provide instruments and assays to NIH. There are no refund provisions under the contract. Consideration from the contract is allocated to each deliverable identified within the contract using a relative fair value allocation method and recognized when there is reasonable assurance the Company will meet the milestones and receive the consideration. Consideration allocated to the delivery of instruments and assays are recognized in accordance with the Company’s existing revenue recognition policy described above. Consideration that relates to capital expenditures is recorded as a reduction to the carrying value of such assets and amortized over the useful life of the ass ets. Consideration allocated to the remainder of the contract is recorded as reductions to the related expense. During the year ended December 31, 2020 , the Company incurred $15.9 million in capital expenditures, which will be reimbursed under this contract as future milestones are met. Therefore, the Company accrued such unbilled receivables in prepaid expenses and other current assets as of December 31, 2020 . Research and Development Costs— Research and development costs are charged to operations as incurred. In conjunction with certain third-party service agreements, the Company is required to make periodic payments based on achievement of certain milestones. The costs related to these research and development services are also charged to operations as incurred. Product Shipment Costs— Product shipment costs are included in sales and marketing expense in the accompanying Consolidated Statements of Income. Shipping and handling costs were $14.2 million, $9.5 million and $8.3 million for the years ended December 31, 2020, 2019 and 2018, respectively. Advertising Costs— Advertising costs are expensed as incurred. Advertising costs were $1.1 million, $1.3 million and $0.9 million for the years ended December 31, 2020, 2019 and 2018, respectively. Income Taxes— Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of the income tax provision. Fair Value of Financial Instruments — The Company uses the fair value hierarchy established in Accounting Standards Codification (“ASC”) Topic 820 , Fair Value Measurements and Disclosures, which requires that the valuation of assets and liabilities subject to fair value measurements be classified and disclosed by the Company in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts receivables, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. Stock-Based Compensation —Compensation expense related to stock options granted is recognized ratably over the service vesting period for the entire option. For stock options with graded vesting, the Company ensures that the cumulative amount of compensation expense recognized at the end of any reporting period at least equals the portion of the stock option that has vested at that date. The total number of stock options expected to vest is adjusted by estimated forfeiture rates. The Company determined the estimated fair value of each stock option on the date of grant using the Black-Scholes option valuation model. The fair value of restricted stock units is determined based on the closing market price of the Company’s common stock on the grant date. Compensation expense for time-based restricted stock units (“RSUs”) is measured at the grant date and recognized ratably over the vesting period. A portion of the restricted stock granted are performance-based and vesting is tied to achievement of specific Company goals over a three-year time period, subject to early vesting upon achievement of the performance goals. For purposes of measuring compensation expense for performance-based restricted stock units (“PSUs”), the number of shares ultimately expected to vest is estimated at each reporting date based on management’s expectations regarding the relevant performance criteria. The grant date of the PSUs takes place when the grant is authorized and the specific achievement goals are communicated. Comprehensive Income —Comprehensive income includes unrealized gains and losses which are related to the cumulative translation adjustments and derivative instruments excluded from the Company’s Consolidated Statements of Income. Use of Estimates —The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Accounting Periods —Each of the Company’s fiscal quarters end on the Sunday closest to the end of the calendar quarter. The Company’s fiscal year ended January 3, 2021 was 53 weeks and the Company’s fiscal years ended December 29, 2019 and December 30, 2018 were 52 weeks. For ease of reference, the calendar year end dates are used herein. Leases— Lease liabilities represent the obligation to make lease payments and right-of-use (“ROU”) assets represent the right to use the underlying asset during the lease term. Lease liabilities and ROU assets are recognized at the commencement date of the lease based on the present value of lease payments over the lease term at the commencement date. When the implicit rate is unknown, an incremental borrowing rate based on the information available at the commencement date is used in determining the present value of the lease payments. Options to extend or terminate the lease are included in the determination of the lease term when it is reasonably certain that the Company will exercise such options. For certain classes of assets, the Company accounts for lease and non-lease components as a single lease component. Variable lease payments, including those related to changes in the consumer price index, are recognized in the period in which the obligation for those payments are incurred and are not included in the measurement of the ROU assets or lease liabilities. Short-term leases are excluded from the calculation of the ROU assets and lease liabilities.

Balance Sheet Account Details (

Balance Sheet Account Details (Notes)	12 Months Ended
	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Supplemental Balance Sheet Disclosures [Text Block]	Balance Sheet Account Details Prepaid expenses and other current assets The following is a summary of prepaid expenses and other current assets (in thousands): December 31, 2020 2019 Unbilled receivables $ 16,041 $ — Other receivables 15,442 7,857 Prepaid expenses 7,335 4,568 Other 2,157 4,445 Total prepaid expenses and other current assets $ 40,975 $ 16,870 Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. The following is a summary of inventories (in thousands): December 31, 2020 2019 Raw materials $ 58,264 $ 23,294 Work-in-process (materials, labor and overhead) 31,359 20,514 Finished goods (materials, labor and overhead) 24,175 14,278 Total inventories $ 113,798 $ 58,086 Property, Plant and Equipment, net The following is a summary of property, plant and equipment (in thousands): December 31, 2020 2019 Equipment, furniture and fixtures $ 91,838 $ 80,599 Building and improvements 49,014 46,878 Leased instruments 60,722 47,656 Land 1,080 1,080 Construction in Progress 32,595 15,748 Total property, plant and equipment, gross 235,249 191,961 Less: accumulated depreciation and amortization (124,768) (112,199) Total property, plant and equipment, net $ 110,481 $ 79,762 Construction in progress includes instruments that have not been placed at a customer under a lease agreement that will be reclassified to leased instruments once placed at a customer site. The total e xpense for depreciation of fixed assets and amortization of leasehold improvements was $20.8 million, $19.4 million and $17.7 million for the years ended December 31, 2020, 2019 and 2018, respectively. Maintenance and minor repairs are charged to operations as incurred. Goodwill and Intangible Assets The Company had goodwill of $337.0 million as of December 31, 2020, which remains consistent with December 31, 2019. Finite-lived intangible assets consisted of the following (dollar amounts in thousands): December 31, 2020 December 31, 2019 Description Weighted-average Gross Accumulated Net Gross Accumulated Net Purchased technology 9.1 $ 112,100 $ (71,426) $ 40,674 $ 112,100 $ (64,632) $ 47,468 Customer relationships 7.0 122,584 (60,688) 61,896 122,178 (44,045) 78,133 License agreements 9.9 6,518 (5,312) 1,206 6,509 (4,931) 1,578 Patent and trademark costs 10.8 28,740 (13,038) 15,702 28,740 (10,331) 18,409 Software development costs 5.0 8,743 (5,790) 2,953 7,432 (4,908) 2,524 Total finite-lived intangible assets $ 278,685 $ (156,254) $ 122,431 $ 276,959 $ (128,847) $ 148,112 Amortization expense related to the capitalized software costs was $0.9 million, $0.8 million and $1.0 million for the years ended December 31, 2020, 2019 and 2018, respectively. Amortization expense (including capitalized software costs) was $27.3 million, $27.5 million and $28.8 million for the years ended December 31, 2020, 2019 and 2018, respectively. The expected future annual amortization expense of the Company’s finite-lived intangible assets held as of December 31, 2020 is as follows (in thousands): For the years ending December 31, Amortization expense 2021 $ 27,452 2022 26,922 2023 26,211 2024 21,634 2025 7,979 Thereafter 12,233 Total $ 122,431 Other current liabilities The following is a summary of other current liabilities (in thousands): December 31, 2020 2019 Customer incentives $ 11,934 $ 7,369 Deferred revenue 3,733 336 Derivative liabilities 3,061 433 Other 13,562 6,724 Total other current liabilities $ 32,290 $ 14,862

Debt

Debt	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Debt	Debt Convertible Senior Notes In December 2014, the Company issued $172.5 million aggregate principal amount of 3.25% Convertible Senior Notes due 2020. The Company accounted separately for the liability and equity components of the Convertible Senior Notes in accordance with authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. The guidance required the carrying amount of the liability component to be estimated by measuring the fair value of a similar liability that does not have an associated conversion feature. Because the Company had no outstanding non-convertible public debt, the Company determined that senior, unsecured corporate bonds traded on the market represent a similar liability to the Convertible Senior Notes without the conversion option. Based on market data available for publicly traded, senior, unsecured corporate bonds issued by companies in the same industry with similar credit ratings and with similar maturity, the Company estimated the implied interest rate of its Convertible Senior Notes to be 6.9%, assuming no conversion option. Assumptions used in the estimate represent what market participants would use in pricing the liability component, which were defined as Level 2 observable inputs. The estimated implied interest rate was applied to the Convertible Senior Notes, which resulted in a fair value of the liability component of $141.9 million upon issuance, calculated as the present value of implied future payments based on the $172.5 million aggregate principal amount. The $30.7 million difference between the cash proceeds of $172.5 million and the estimated fair value of the liability component was recorded in additional paid-in capital, net of tax and issuance costs, as the Convertible Senior Notes were not considered redeemable. During 2020 the remaining aggregate principal amount of Convertible Senior Notes were settled or matured on December 15, 2020 and at December 31, 2020 no amounts were outstanding. The following table summarizes the amount of interest expense for the following periods (in thousands): Year ended December 31, 2020 2019 2018 Amortization of debt discount and deferred issuance costs $ 368 $ 1,179 $ 3,094 Coupon interest 195 1,103 2,992 Total Interest Expense $ 563 $ 2,282 $ 6,086 The following table summarizes information about the settlement of the Convertible Senior Notes during the year ended December 31, 2020 (dollars in thousands): Year ended December 31, 2020 Principal amount settled $ 13,131 Number of shares of common stock issued 225,955 Payment on Convertible Senior Note and Derivative Liability $ 43,446 Revolving Credit Facility On August 31, 2018, the Company entered into an Amended and Restated Credit Agreement (the “Credit Agreement”) which provides the Company with a $175.0 million Revolving Credit Facility. The Company repaid the remaining principal during the year ended December 31, 2019 and no balance remained outstanding as of December 31, 2020. The Credit Agreement has a term of five years and matures on August 31, 2023. Loans will bear interest at a rate equal to (i) the London Interbank Offered Rate (“LIBOR”) plus the “applicable rate” or (ii) the “base rate” (defined as the highest of (a) the Bank of America prime rate, (b) the Federal Funds rate plus one-half of one percent and (c) LIBOR plus one percent) plus the “applicable rate.” The applicable rate is determined in accordance with a pricing grid based on the Company’s Consolidated Leverage Ratio (as defined in the Credit Agreement) ranging from 1.75% to 2.50% per annum for LIBOR rate loans and from 0.75% to 1.50% per annum for base rate loans. In addition, the Company pays a commitment fee on the unused portion of the Credit Agreement based on the Company’s Consolidated Leverage Ratio ranging from 0.15% to 0.30% per annum. The Revolving Credit Facility is guaranteed by certain material domestic subsidiaries of the Company (the “Guarantors”) and is secured by liens on substantially all of the assets of the Company and the Guarantors, excluding real property and certain other types of excluded assets, and contains affirmative and negative covenants that are customary for credit agreements of this nature. The negative covenants include, among other things, limitations on asset sales, mergers, indebtedness, liens, dividends and other distributions, investments and transactions with affiliates. The Credit Agreement contains two financial covenants: (i) maximum Consolidated Leverage Ratio (as defined in the Credit Agreement) as of the last day of each fiscal quarter of 3.50 to 1.00, which ratio may be increased to 4.50 to 1.00 in case of certain qualifying acquisitions; and (ii) a minimum Consolidated Fixed Charge Coverage Ratio (as defined in the Credit Agreement) of 1.25 to 1.00 as of the end of any fiscal quarter for the most recently completed four fiscal quarters. The Company was in compliance with all financial covenants as of December 31, 2020.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Significant components of the provision (benefit) for income taxes are as follows (in thousands): December 31, 2020 2019 2018 Current: Federal $ 198,498 $ 1,559 $ — State 34,608 746 755 Foreign 1,136 2,007 6,575 Total current provision 234,242 4,312 7,330 Deferred: Federal (2,855) 1,234 (9,970) State (1,104) (1,186) (7,944) Foreign (251) (103) (215) Total deferred (benefit) provision (4,210) (55) (18,129) Provision (benefit) for income taxes $ 230,032 $ 4,257 $ (10,799) The Company’s income before income taxes was subject to taxes in the following jurisdictions for the following periods (in thousands): December 31, 2020 2019 2018 United States $ 1,035,752 $ 70,606 $ 46,592 Foreign 4,567 6,572 16,792 Income before income taxes $ 1,040,319 $ 77,178 $ 63,384 Significant components of the Company’s deferred tax assets and deferred tax liabilities as of December 31, 2020 and 2019 are shown below (in thousands): December 31, 2020 2019 Deferred tax assets: Lease liability $ 24,790 $ 22,009 Intangible assets 2,747 3,951 Allowance for returns and discounts 27,277 5,266 Stock-based compensation 8,367 5,197 Tax credit carryforwards 11,770 13,846 Other, net 10,426 6,610 Total deferred tax assets 85,377 56,879 Valuation allowance for deferred tax assets (2,281) (2,353) Total deferred tax assets, net of valuation allowance 83,096 54,526 Deferred tax liabilities: Right-of-use assets (22,969) (20,334) Intangible assets (1,133) (1,633) Property, plant and equipment (14,232) (8,057) Total deferred tax liabilities (38,334) (30,024) Net deferred tax assets $ 44,762 $ 24,502 Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. For the three years ended December 31, 2020, the Company has demonstrated positive cumulative pre-tax book income. Such objective positive evidence allowed the Company to consider other subjective evidence, such as the Company’s projections for future profitability, to determine the realizability of its deferred tax assets. On the basis of this evaluation, during the year ended December 31, 2020, the Company decreased the valuation allowance by $0.1 million related to the U.S. Foreign Tax Credit. The valuation allowance of $2.3 million as of December 31, 2020 represents the portion of the deferred tax asset that management could not conclude was more likely than not to be realized. The amount of the deferred tax assets considered realizable could be adjusted in the future based on changes in available positive and negative evidence. As of December 31, 2020, the Company had no federal net operating loss (“NOL”) carryforwards. The Company had state NOLs of approximately $5.9 million which will begin to expire in 2030 unless previously utilized. The Company has no federal research credits. The Company has federal foreign tax credits of $2.3 million which will begin to expire on December 31, 2028 unless previously utilized. The Company has state research credits of $12.3 million, of which none expire. Pursuant to Internal Revenue Code Sections 382 and 383, the Company’s use of its NOL and tax credit carryforwards may be limited as a result of cumulative changes in ownership of more than 50% over a three The reconciliation of income tax computed at the federal statutory rate to the provision (benefit) for income taxes from continuing operations is as follows (in thousands): Year ended December 31, 2020 2019 2018 Tax expense at statutory tax rate $ 218,467 $ 16,207 $ 13,311 State tax expense, net of federal tax 30,289 1,061 1,526 Permanent differences 3,843 611 635 Federal and state research credits—current year (5,037) (4,269) (3,628) Stock-based compensation (13,867) (10,408) (9,286) Change in valuation allowance (72) 523 (13,374) Foreign Derived Intangible Income Deduction (FDII) (8,589) (159) (786) Other 4,998 691 803 Provision (benefit) for income taxes $ 230,032 $ 4,257 $ (10,799) The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes. The following table summarizes the activity related to the Company’s unrecognized tax benefits (in thousands): Year ended December 31, 2020 2019 2018 Beginning balance $ 17,236 $ 15,245 $ 9,565 (Decreases) increases related to prior year tax positions (2,351) 287 (558) Increases related to current year tax positions 7,726 2,209 6,238 Expiration of the statute of limitations for the assessment of taxes (54) (505) — Ending balance $ 22,557 $ 17,236 $ 15,245 As of December 31, 2020, 2019 and 2018, the Company had unrecognized tax benefits of $22.6 million, $17.2 million, and $15.2 million respectively, of which $15.0 million and $11.1 million and $9.3 million, respectively, would reduce the Company’s annual effective tax rate, if recognized. It is reasonably possible that the amount of unrecognized tax benefits in various jurisdictions may decrease in the next 12 months due to settlements with tax authorities. However, due to the uncertainty surrounding the timing of these events, an estimate in the change within the next 12 months cannot be made at this time. The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of the income tax expense. The Company had accrued interest and penalties associated with uncertain tax positions of $0.5 million as of December 31, 2020, $0.4 million as of December 31, 2019 and $0.3 million as of December 31, 2018. Interest expense, net of accrued interest (reversed), was approximately $0.1 million for the years ended December 31, 2020, 2019 and 2018. The Company is subject to periodic audits by domestic and foreign tax authorities. As of December 31, 2020, the Company no longer has any federal net operating loss or credit carryforwards. However, because of utilization of tax attributes generated in tax years 2012 and later on its tax returns still open by statute, the Company’s federal tax years from 2012 and forward are still subject to examination by tax authorities. Due to the carryforward of unutilized California net operating losses and credits, the Company’s California tax returns for years 2001 and forward are subject to examination by tax authorities. The Company believes that it has appropriate support for the income tax positions taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on an assessment of many factors, including past experience and interpretations of tax law applied to the facts of each matter. The Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted on March 27, 2020. The CARES Act provides for, among other things, refundable payroll tax credits, deferment of employer side social security payments and technical amendments regarding the income tax depreciation of qualified improvement property placed in service after December 31, 2017. The Company is benefiting only from the technical amendments regarding retroactive accelerated income tax depreciation on certain of our leasehold improvement assets.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Stockholders' Equity	Note 5. Stockholders’ Equity Preferred Stock. The Company’s certificate of incorporation, as amended, authorizes the issuance of up to 5 million preferred shares. The Board of Directors is authorized to fix the number of shares of any series of preferred stock and to determine the designation of such shares. However, the amended certificate of incorporation specifies the initial series and the rights of that series. No shares of preferred stock were outstanding as of December 31, 2020, 2019 or 2018. Equity Incentive Plan. The Company grants stock options, RSUs and PS Us to employees and non-employee directors under its 2018 Equity Incentive Plan (the “2018 Plan”). The Company previously granted stock options under its 2016 Equity Incentive Plan (the “2016 Plan”), Amended and Restated 2010 Equity Incentive Plan (the “2010 Plan”) and the Amended and Restated 2001 Equity Incentive Plan (the “2001 Plan”). The 2016 Plan, 2010 Plan and 2001 Plan were terminated at the time of adoption of the 2018 Plan, but the terminated Plans continue to govern outstanding options granted thereunder. The Company has stock options, RSUs and PSUs outstanding, which were issued under each of these equity incentive plans to certain employees and directors. Stock options granted under these plans have terms ranging up to ten years, have exercise prices ranging from $14.56 to $248.41 per share, and generally vest over four years. As of December 31, 2020, approximately 2.2 million shares remained available for grant and 3.8 million shares of common stock were reserved for future issuance under the 2018 Plan. Restricted Stock Units. The Company grants b oth RSU s and PSUs to certain officers, directors and management. Until the restrictions lapse, ownership of the affected restricted stock units granted to the Company’s officers, directors and management is conditional upon continuous employment with the Company. For the years ended December 31, 2020, 2019 and 2018, the Company granted approximately 0.2 million, 0.3 million and 0.2 million shares, respectively, of RSUs to Board of Directors, officers and management, which either have a time-based four-year vesting provision or performance-based vesting provisions. During the years ended December 31, 2020, 2019 and 2018, RSUs were granted to certain members of the Board of Directors in lieu of cash compensation as a part of the Company’s non-employee director’s deferred compensation program. The compensation expense associated with these RSU grants were $0.5 million, $0.5 million and $0.4 million for the years ended December 31, 2020, 2019 and 2018, respectively. Employee Deferred Bonus Compensation Program. For the years ended December 31, 2020, 2019 and 2018, certain employees of the Company were eligible to participate in the Company’s deferred bonus compensation program with respect to any payments received under the Company’s cash incentive plan. Participating employees could elect to receive 50% or 100% of the cash value of their cash bonus in the form of fully vested RSUs plus a premium as additional RSUs, issued under the 2018 Plan. The premium RSUs are subject to a one-year vesting requirement from the date of issuance. The additional premium will be determined based on the length of time of the deferral period selected by the participating employee as follows: (i) if one year from the date of grant, a premium of 10% on the amount deferred, (ii) if two years from the date of grant, a premium of 20% on the amount deferred, or (iii) if four years from the date of grant, a premium of 30% on the amount deferred. Employee Stock Purchase Plan. Under the Company’s Amended and Restated 1983 Employee Stock Purchase Plan (the “ESPP”), full-time employees are allowed to purchase common stock through payroll deductions (which cannot exceed 10% of the employee’s compensation) at the lower of 85% of fair market value at the beginning or end of each six-month purchase period. As of December 31, 2020, 86,571 shares remained available for future issuance. Share Repurchase Program. On December 12, 2018, the Board of Directors authorized a stock repurchase program pursuant to which up to $50.0 million of the Company’s shares of common stock may be purchased through December 12, 2020. On August 28, 2020, the Board authorized an increase of additional $150.0 million to the Company’s existing stock repurchase program and also extended the repurchase authorization through August 28, 2022. During the year ended December 31, 2020, 257,329 shares of outstanding common stock were repurchased under the revised share repurchase program. There were no repurchases during 2019. At December 31, 2020, $156.3 million remained available under the new repurchase program.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation expense was as follows (in thousands): Year ended December 31, 2020 2019 2018 Cost of sales $ 2,012 $ 1,162 $ 763 Research and development 3,372 2,332 2,266 Sales and marketing 6,009 3,497 2,843 General and administrative 9,626 6,261 5,837 Total stock-based compensation expense $ 21,019 $ 13,252 $ 11,709 For the years ended December 31, 2020, 2019 and 2018, the Company recorded $2.2 million, $1.4 million and $1.6 million in stock-based compensation expense, respectively, associated with the deferred bonus compensation program, described in Note 5. During the years ended December 31, 2020, 2019 and 2018, $2.1 million, $0.8 million and $1.6 million, respectively, was initially recorded as a component of accrued payroll and related expenses associated with the deferred bonus compensation program. Stock Options Compensation expense related to stock options granted is recognized ratably over the service vesting period for the entire option award. The estimated fair value of each stock option was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions: Year ended December 31, 2020 2019 2018 Risk-free interest rate 1.18 % 2.51 % 2.49 % Expected option life (in years) 5.12 5.68 6.29 Volatility rate 41 % 39 % 36 % Dividend rate 0 % 0 % 0 % The computation of the expected option life is based on a weighted-average calculation combining the average life of options that have already been exercised and post-vest cancellations with the estimated life of the remaining vested and unexercised options. The expected volatility is based on the historical volatility of the Company’s stock. The risk-free interest rate is based on the U.S. Treasury yield curve over the expected term of the option. The Company has never paid any cash dividends on its common stock, and does not anticipate paying any cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield of zero in the Black-Scholes option valuation model. The Company’s estimated forfeiture rate is based on its historical experience and future expectations. The Company’s determination of fair value is affected by the Company’s stock price as well as a number of assumptions that require judgment. The weighted-average fair value per share was $36.84, $23.67 and $18.76 for options granted during the years ended December 31, 2020, 2019 and 2018, respectively. The total intrinsic value was $51.8 million, $49.8 million and $38.2 million for options exercised during the years ended December 31, 2020, 2019 and 2018, respectively. As of December 31, 2020, total unrecognized compensation expense related to stock options was approximately $7.1 million and the related weighted-average period over which it is expected to be recognized is approximately 2.0 years. The maximum contractual term of the Company’s stock options is ten years. A summary of the status of stock option activity for the years ended December 31, 2018, 2019 and 2020 is as follows (in thousands, except price data and years): Number Weighted- Weighted- Aggregate Outstanding at December 31, 2017 2,659 $ 18.54 Granted 159 46.50 Exercised (891) 17.07 Forfeited (50) 21.19 Outstanding at December 31, 2018 1,877 21.53 Granted 169 59.18 Exercised (1,091) 19.22 Forfeited (11) 49.71 Outstanding at December 31, 2019 944 30.63 Granted 145 96.34 Exercised (317) 21.03 Forfeited (12) 43.34 Outstanding at December 31, 2020 760 $ 46.95 6.79 $ 101,535 Vested and expected to vest at December 31, 2020 739 $ 46.03 6.74 $ 99,456 Exercisable at December 31, 2020 327 $ 23.32 5.16 $ 51,062 Restricted Stock Units A summary of the status of restricted stock unit activity for the years ended December 31, 2018, 2019 and 2020 is as follows (in thousands, except price data): Shares Weighted-average Non-vested at December 31, 2017 746 $ 20.88 Granted 242 49.97 Vested (296) 21.70 Forfeited (16) 28.40 Non-vested at December 31, 2018 676 30.75 Granted 279 59.75 Vested (148) 24.26 Forfeited (21) 43.90 Non-vested at December 31, 2019 786 41.88 Granted 235 101.20 Vested (123) 26.58 Forfeited (20) 58.32 Non-vested at December 31, 2020 878 $ 59.60

Earnings (Loss) Per Share (Note

Earnings (Loss) Per Share (Notes)	12 Months Ended
	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Earnings Per Share [Text Block]	Earnings Per Share Basic earnings per share (“EPS”) is computed by dividing net income by the weighted-average number of common shares outstanding. Diluted EPS is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of shares issuable from stock options, unvested RSUs and the 3.25% Convertible Senior Notes. Potentially dilutive common shares from outstanding stock options and unvested RSUs are determined using the average share price for each period under the treasury stock method. Potentially dilutive shares from the Convertible Senior Notes are determined using the if-converted method. Under the provisions of the if-converted method, the Convertible Senior Notes are assumed to be converted and the resulting common shares are included in the denominator of the EPS calculation and the interest expense, net of tax, recorded in connection with the Convertible Senior Notes is added back to net income. The Convertible Senior Notes have a dilutive impact when the average market price of the Company’s common stock exceeds the applicable conversion price of the notes. The Convertible Senior Notes became convertible on March 31, 2018 and matured on December 15, 2020. The following table reconciles net income and the weighted-average shares used in computing basic and diluted EPS in the respective periods (in thousands): Year ended December 31, 2020 2019 2018 Numerator: Net income used for basic earnings per share $ 810,287 $ 72,921 $ 74,183 Interest expense on Convertible Senior Notes, net of tax 445 1,848 4,927 Net income used for diluted earnings per share, if-converted method $ 810,732 $ 74,769 $ 79,110 Basic weighted-average common shares outstanding 42,124 40,860 37,995 Dilutive potential shares issuable from Convertible Senior Notes 295 1,062 2,850 Dilutive potential shares issuable from stock options and unvested RSUs 1,172 1,189 1,709 Diluted weighted-average common shares outstanding, if-converted 43,591 43,111 42,554 Potentially dilutive shares excluded from calculation due to anti-dilutive effect 10 199 161

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Leases We lease administrative, research and development, sales and marketing and manufacturing facilities and certain equipment under various non-cancelable lease agreements. Facility leases generally provide for periodic rent increases, and may contain clauses for rent escalation, renewal options or early termination. The components of lease expense and supplemental cash flow information related to leases during the respective periods are as follows (in thousands): Year ended December 31, 2020 2019 Finance lease ROU asset amortization $ 303 $ 314 Finance lease interest expense 877 835 Total finance lease costs 1,180 1,149 Operating lease costs 11,236 10,130 Total lease costs $ 12,416 $ 11,279 Cash paid for amounts included in the measurement of operating lease liabilities Operating cash flows from operating leases $ 10,801 $ 9,385 Operating cash flows from finance leases $ 877 $ 835 ROU assets obtained in exchange for new lease liabilities Operating leases $ 15,271 $ 12,231 Finance leases $ — $ 1,369 The Company leases its facilities and certain equipment. Commitments for minimum rentals under non-cancelable leases at the end of 2020 are as follows (dollars in thousands): Years ending December 31, Operating Finance 2021 $ 12,043 $ 1,215 2022 11,396 1,258 2023 11,281 1,277 2024 11,226 1,098 2025 11,327 1,019 Thereafter 79,893 12,420 Total lease payments 137,166 18,287 Less: imputed interest (28,661) (13,949) Total 108,505 4,338 Less: current portion (7,799) (238) Non-current portion $ 100,706 $ 4,100 Weighted average remaining lease term 14.3 years 12.6 years Weighted average discount rate 4 % 27 % Summers Ridge Lease — The Company leases three of the four buildings that are located on the Summers Ridge Property in San Diego, California with an initial term through January 2033 with options to extend the lease for two additional five-year terms upon satisfaction of certain conditions, which have not been included in the determination of the lease term. The lease is subject to must-take provisions related to one additional building, which will have the same lease term as the three buildings originally leased. The remaining building is subject to the expiration of the lease with its current tenant for which the expiration date is not yet known. McKellar Lease — During 1999, the Company completed a sale and leaseback transaction of its San Diego facility at McKellar Court to a partnership for which the Company is a 25% limited partner. The partnership is deemed to be a variable interest entity (VIE). The Company is not, however, the primary beneficiary of the VIE as it does not have the power to direct the activities of the partnership and does not have the obligation to absorb losses or receive benefits of the partnership that could potentially be significant to the partnership. The Company made lease payments to the partnership of approximately $1.0 million, $1.0 million and $0.9 million for the years ended December 31, 2020, 2019 and 2018, respectively. Rutherford Lease — During January 2021, the Company entered into a lease agreement for a manufacturing facility in Carlsbad, California. The minimum lease payments related to the lease is approximately $70.5 million. The initial lease term is 15 years with options to extend the lease for two additional five-year periods. Purchase Commitments The Company has $32.1 million in firm inventory purchase commitments as of December 31, 2020, the majority of which will be purchased within the next twelve months. Litigation and Other Legal Proceedings In Beckman Coulter Inc. v. Quidel Corporation, which was filed in the Superior Court for the County of San Diego, California, on November 27, 2017, Beckman Coulter (“Beckman”) alleges that a provision of an agreement between Quidel and Beckman violates state antitrust laws. Our acquisition of the B-type Naturietic Peptide assay business (“BNP Business”) consisted of assets and liabilities relating to a contractual arrangement with Beckman (the “Beckman Agreement”) for the supply of antibodies and other inputs related to, and distribution of, the Triage® BNP Test for the Beckman Coulter Access Family of Immunoassay Systems. The Beckman Agreement further provides that Beckman, for a specified period, cannot research, develop, manufacture or sell an assay for use in the diagnosis of cardiac diseases that measures or detects the presence or absence of BNP or NT-pro-BNP (a related biomarker) (the “Exclusivity Provision”). In the lawsuit, Beckman asserts that this provision violates certain state antitrust laws and is unenforceable. Beckman contends that it has suffered damages due to this provision and seeks a declaration that this provision is void. On December 7, 2018, the trial court granted a motion by Beckman for summary adjudication, holding that the Exclusivity Provision is void under California law (the “December 7 Order”). On December 18, 2018, the trial court stayed the effect of the December 7 Order pending a decision on a writ petition Quidel intended to file with the Court of Appeal. Quidel filed its writ petition on January 18, 2019, asking the Court of Appeal to review and reverse the December 7 Order. On February 7, 2019, the trial court stayed all the remaining litigation pending the outcome of the writ petition and vacated all deadlines in the case. On March 14, 2019, the Court of Appeal issued an order to show cause why the relief sought in Quidel’s petition should not be granted. The Court also stayed the December 7 Order pending a further order from the Court of Appeal. On August 29, 2019, the Court of Appeal issued a written decision ruling in Quidel’s favor and overturning the December 7 Order. Beckman challenged the Court of Appeal’s ruling with a petition for rehearing on September 10, 2019, which was denied on September 13, 2019. On October 1, 2019, Beckman filed a petition for review of the Court of Appeal’s ruling with the Supreme Court of California (the “Supreme Court”). We subsequently filed an answer to Beckman’s petition, Beckman filed a response to our reply and on November 13, 2019, the Supreme Court granted review of the Court of Appeal ruling, with further action in this matter being deferred pending consideration and disposition of a related issue in Ixchel Pharma v. Biogen , or pending further order of the Supreme Court. On August 3, 2020, the Supreme Court issued its opinion in Ixchel Pharma v. Biogen , holding, among other matters, that in evaluating whether a restraint in a business-to-business agreement violates California law, “a rule of reason applies to determine the validity of a contractual provision by which a business is restrained from engaging in a lawful trade or business with another business.” That is, the Supreme Court rejected the position that every contract in restraint of trade in the business context is per se void, but rather each must be evaluated based on a rule of reason. On September 9, 2020, the Supreme Court transferred the matter back to the Court of Appeal with directions to vacate its decision and reconsider the case in light of the Supreme Court’s Ixchel Pharma v. Biogen ruling. On November 6, 2020, the Court of Appeal issued its opinion, granting our petition and directing the trial court to vacate its December 7, 2018 order granting Beckman’s motion for summary adjudication. On January 20, 2021, the Court of Appeal issued a remittitur, certifying its November 6, 2020 opinion and transferring the case back to the trial court where the litigation will continue and the exclusivity provision will be evaluated under a rule of reason analysis under California law. The stay remains in place at the trial court level and a status conference is scheduled for March 12, 2021. Quidel denies that the Exclusivity Provision is unlawful, denies any liability with respect to this matter, and intends to vigorously defend itself. There are multiple factors that prevent us from being able to estimate the amount of loss, if any, that may result from this matter including: (1) we are vigorously defending ourselves and believe that we have a number of meritorious legal defenses; (2) there are unresolved questions of law and fact that could be important to the ultimate resolution of this matter, some of which are subject to review by the Supreme Court; and (3) discovery is ongoing. Accordingly, at this time, we are not able to estimate a possible loss or range of loss that may result from this matter or to determine whether such loss, if any, would have a material adverse effect on our financial condition, results of operations or liquidity. From time to time, the Company is involved in other litigation and proceedings, including matters related to product liability claims, commercial disputes and intellectual property claims, as well as regulatory, employment, and other claims related to our business. The Company accrues for legal claims when, and to the extent that, amounts associated with the claims become probable and are reasonably estimable. The actual costs of resolving legal claims may be substantially higher or lower than the amounts accrued for those claims. For those matters as to which we are not able to estimate a possible loss or range of loss, we are not able to determine whether the loss will have a material adverse effect on our business, financial condition or results of operations or liquidity. No accrual has been recorded as of December 31, 2020 and December 31, 2019 related to such matters as they are not probable and/or reasonably estimable. Management believes that all such current legal actions, in the aggregate, will not have a material adverse effect on the Company. However, the resolution of, or increase in any accruals for, one or more matters may have a material adverse effect on the Company’s results of operations and cash flows. The Company also maintains insurance, including coverage for product liability claims, in amounts that management believes are appropriate given the nature of its business. Licensing Arrangements The Company has entered into various licensing and royalty agreements, which largely require payments by the Company based on specified product sales as well as the achievement of specified milestones. The Company had royalty and license expenses relating to those agreements of approximately $2.4 million, $1.1 million and $0.4 million for the years ended December 31, 2020, 2019 and 2018, respectively.

Industry and Geographic Informa

Industry and Geographic Information	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Industry and Geographic Information	The Company operates in one reportable segment. Sales to customers outside the U.S. represented 13%, 33% and 32% of total revenue for the years ended December 31, 2020, 2019 and 2018, respectively, of which sales to customers in China comprised 4%, 13% and 10%, respectively. As of December 31, 2020 and 2019, net accounts receivable due from foreign customers were $18.6 million and $22.9 million, respectively. For the year ended December 31, 2020, sales of our coronavirus products accounted for 70% of total revenue. For the years ended December 31, 2020, 2019 and 2018, sales of our influenza products accounted for 8%, 26%, and 24% respectively, of total revenue. The Company had sales to individual customers in excess of 10% of total revenue, as follows: Year ended December 31, 2020 2019 2018 Customer: A 29 % 13 % 12 % B 16 % 18 % 19 % C 13 % 5 % 5 % D 10 % 15 % 13 % 68 % 51 % 49 % As of December 31, 2020 and 2019, net accounts receivable from individual customers with balances due in excess of 10% of total accounts receivable totaled $411.7 million and $53.5 million, respectively. The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory (in thousands): Long-lived assets as of December 31, Total revenue 2020 2019 2020 2019 2018 Domestic $ 108,375 $ 78,254 $ 1,452,329 $ 358,381 $ 354,895 Foreign 2,106 1,508 209,339 176,509 167,390 Total $ 110,481 $ 79,762 $ 1,661,668 $ 534,890 $ 522,285 Consolidated total revenues by product category are as follows (in thousands): Year ended December 31, 2020 2019 2018 Rapid Immunoassay $ 1,144,831 $ 191,736 $ 183,160 Cardiometabolic Immunoassay 242,933 266,505 266,524 Molecular Diagnostic Solutions 222,964 21,716 19,358 Specialized Diagnostic Solutions 50,940 54,933 53,243 Total revenues $ 1,661,668 $ 534,890 $ 522,285

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement The following table presents the Company’s hierarchy for its assets and liabilities measured at fair value on a recurring basis as of the following periods (in thousands): December 31, 2020 December 31, 2019 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Cash equivalents (money market funds) $ 200,003 $ — $ — $ 200,003 $ — $ — $ — $ — Derivative assets — 24 — 24 — 321 — 321 Total assets measured at fair value $ 200,003 $ 24 $ — $ 200,027 $ 321 $ — $ 321 Liabilities: Derivative liabilities $ — $ 3,061 $ — $ 3,061 $ — $ 433 $ — $ 433 Contingent consideration — — 11,896 11,896 — — 16,535 16,535 Deferred consideration — 115,951 — 115,951 — 151,382 — 151,382 Total liabilities measured at fair value $ — $ 119,012 $ 11,896 $ 130,908 $ — $ 151,815 $ 16,535 $ 168,350 There were no transfers of assets or liabilities between Level 1, Level 2, and Level 3 categories of the fair value hierarchy during the years ended December 31, 2020 and 2019. Cash equivalents consistent of funds held in money market accounts that are valued using quoted prices in active markets for identical instruments. Derivative financial instruments are based on observable inputs that are corroborated by market data. Observable inputs include broker quotes and daily market foreign currency rates and forward pricing curves. In connection with the acquisition of the BNP Business, the Company pays annual installments of $42.0 million each in deferred consideration through April 2023 and up to $8.0 million each in contingent consideration through April 2022. The fair value of the deferred consideration is calculated based on the net present value of cash payments using an estimated borrowing rate based on a quoted price for a similar liability. The fair value of contingent consideration is calculated using a discounted probability weighted valuation model. Discount rates used in such calculation is a significant assumption that is not observed in the market and, therefore, the resulting fair value represents a Level 3 measurement. The Company assesses the fair value of contingent consideration to be settled in cash related to these prior acquisitions using a discounted revenue model. Significant assumptions used in the measurement include revenue projections and discount rates. This fair value measurement of contingent consideration is based on significant inputs not observed in the market and thus represent Level 3 measurements. The changes in fair value of the contingent considerations during the years ended 2020, 2019 and 2018 were due to changes in the estimated payments and discounting periods. Changes in estimated fair value of contingent consideration liabilities from December 31, 2017 through December 31, 2020 are as follows (in thousands): Contingent consideration Balance at December 31, 2017 $ 24,301 Cash payments (6,303) Change in estimated fair value, recorded in general and administrative expenses 1,114 Balance at December 31, 2018 19,112 Cash payments (4,044) Change in estimated fair value, recorded in general and administrative expenses 1,467 Balance at December 31, 2019 16,535 Cash payments (6,044) Change in estimated fair value, recorded in general and administrative expenses 1,405 Balance at December 31, 2020 $ 11,896

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2020
Retirement Benefits [Abstract]
Employee Benefit Plan	Note 11. Employee Benefit Plan The Company has a defined contribution 401(k) plan (the “401(k) Plan”) covering all employees who are eligible to join the 401(k) Plan upon employment. Employee contributions are subject to a maximum limit by federal law. This Plan includes an employer match of 50% on the first 6% of pay contributed by the employee. The Company contributed approximately $3.1 million, $2.5 million and $2.6 million to the 401(k) Plan during the years ended December 31, 2020, 2019 and 2018, respectively.

Derivatives and Hedging (Notes)

Derivatives and Hedging (Notes)	12 Months Ended
	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Hedging	Foreign Currency Hedges In the normal course of business, the Company is exposed to gains and losses resulting from fluctuations in foreign currency exchange rates. As part of its strategy to manage the level of exposure to the risk of fluctuations in foreign currency exchange rates, the Company uses designated cash flow hedges in the form of foreign currency forward contracts to mitigate the impact of foreign currency translation on transactions that are denominated primarily in the Euro and the Chinese Yuan. The Company also uses non-designated forward contracts to hedge non-functional currency denominated balance sheet assets. Hedging relationships for all derivative hedges and the underlying hedged items, as well as the risk management objectives and strategies for undertaking the hedge transactions are formally documented. The Company does not use any derivative financial instruments for trading or other speculative purposes. Such forward foreign currency contracts are carried at fair value in prepaid expenses and other current assets or other current liabilities depending on the unrealized gain or loss position of the hedged contract as of the balance sheet date. Changes in the value of the derivatives are recorded to other comprehensive income (loss) until the underlying hedged item is recognized in earnings, or the derivative no longer qualifies as a highly effective hedge. The cash flows from derivatives treated as hedges are classified in the Consolidated Statements of Cash Flows in the same category as the item being hedged. The notional principal amounts for outstanding derivative instruments provide one measure of the transaction volume outstanding and do not represent the amount of our exposure to credit or market loss. Credit risk represents our gross exposure to potential accounting loss on derivative instruments that are outstanding or unsettled if all counterparties failed to perform according to the terms of the contract, based on then-current currency exchange rates at each respective date. We generally enter into master netting arrangements, which reduces credit risk by permitting net settlement of transactions with the same counterparty. We present our derivative assets and derivative liabilities at their net fair values. We did not have any derivative instruments with credit-risk related contingent features that would require us to post collateral. The following table summarizes the fair value and notional amounts of the foreign currency forward contracts as of December 31, 2020 and December 31, 2019 (in thousands): December 31, 2020 December 31, 2019 Notional Amount Fair Value, Net Notional Amount Fair Value, Net Designated cash flow hedges: Prepaid expenses and other current assets $ — $ — $ 27,944 $ 321 Other current liabilities $ 38,435 $ 2,819 $ 6,219 $ 433 Non-designated forward contracts: Prepaid expenses and other current assets $ 18,160 $ 24 $ — $ — Other current liabilities $ 23,120 $ 242 $ — $ —

Selected Quarterly Financial Da

Selected Quarterly Financial Data (unaudited)	12 Months Ended
	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data (unaudited)	Selected Quarterly Financial Data (unaudited) First Quarter Second Quarter Third Quarter Fourth Quarter (in thousands, except per share data) 2020 Total revenues $ 174,653 $ 201,754 $ 476,058 $ 809,203 Gross profit $ 114,991 $ 148,751 $ 383,619 $ 701,494 Operating income $ 51,628 $ 83,663 $ 307,959 $ 617,076 Net income $ 40,237 $ 67,652 $ 232,268 $ 470,130 Basic income per share $ 0.96 $ 1.61 $ 5.52 $ 11.14 Diluted income per share $ 0.93 $ 1.55 $ 5.33 $ 10.78 2019 Total revenues $ 147,968 $ 108,252 $ 126,492 $ 152,178 Gross profit $ 90,927 $ 59,179 $ 75,859 $ 94,840 Operating income $ 31,153 $ 5,818 $ 20,682 $ 35,063 Net income $ 24,844 $ 1,270 $ 16,181 $ 30,626 Basic earnings per share $ 0.63 $ 0.03 $ 0.39 $ 0.73 Diluted earnings per share $ 0.60 $ 0.03 $ 0.38 $ 0.71

Consolidated Valuation and Qual

Consolidated Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2020
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Consolidated Valuation and Qualifying Accounts	SCHEDULE II QUIDEL CORPORATION CONSOLIDATED VALUATION AND QUALIFYING ACCOUNTS Description Balance at Additions charged to expense or as reductions to revenue (1) Deductions (2) Balance at end of (in thousands) Year ended December 31, 2020: Accounts receivable allowance $ 15,960 $ 276,988 $ (189,513) $ 103,435 Year ended December 31, 2019: Accounts receivable allowance $ 11,979 $ 65,649 $ (61,668) $ 15,960 Year ended December 31, 2018: Accounts receivable allowance $ 12,309 $ 65,142 $ (65,472) $ 11,979 (1) Primarily represents charges for contract rebate allowances recorded as reductions to revenue. Additions to allowance for doubtful accounts are recorded to sales and marketing expense. (2) The deductions represent actual charges against the accrual described above.

Company Operations and Summar_2

Company Operations and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Consolidation	Consolidation— The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Cash and Cash Equivalents	Cash and Cash Equivalents— The Company considers cash equivalents to be highly liquid investments with a maturity at the date of purchase of three months or less. The Company invests its cash equivalents primarily in money market funds with high quality institutions.
Accounts Receivable	Accounts Receivable— The Company sells its products directly to hospitals and reference laboratories as well as to distributors in the U.S. and internationally (see Note 9). The Company periodically assesses the financial strength of these customers and establishes reserves for anticipated losses when necessary, which historically have not been material. The balance of accounts receivable is net of reserves of $103.4 million and $16.0 million at December 31, 2020 and 2019, respectively, of which the reserve related to contract rebates was $100.8 million and $15.7 million, respectively.
Concentration of Credit Risk	Concentration of Credit Risk— Financial instruments that potentially subject the Company to significant concentrations of credit risk consists principally of trade accounts receivable and cash equivalents. The Company performs credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary, but generally requires no collateral. Credit quality is monitored regularly by reviewing credit history. The Company believes that the concentration of credit risk in its trade accounts receivables is moderated by its credit evaluation process, relatively short collection terms, the high level of credit worthiness of its customers, and letters of credit issued on the Company’s behalf. Potential credit losses are limited to the gross value of accounts receivable.
Inventories	Inventories—Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. The Company reviews the components of its inventory periodically for excess, obsolete and impaired inventory and records a reduction to the carrying value when identified.
Property, Plant and Equipment	Property, Plant and Equipment—Property, plant and equipment is recorded at cost and depreciated over the estimated useful lives of the assets ( three
Intangible Assets	Goodwill and Intangible Assets—Intangible assets are recorded at cost and amortized on a straight-line basis over their estimated useful lives, except for indefinite-lived intangibles such as goodwill. Software development costs associated with software to be leased or otherwise marketed are expensed as incurred until technological feasibility has been established. After technological feasibility is established, software development costs are capitalized and amortized on a straight-line basis over the estimated product life.
Convertible Debt	Convertible Debt— The Company accounts for convertible debt instruments that may be settled in cash upon conversion (including combination settlement of cash equal to the “principal portion” and delivery of the “share amount” in excess of the conversion value over the principal portion in shares of common stock and/or cash) by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate. The Company determines the carrying amount of the liability component by measuring the fair value of similar debt instruments that do not have the conversion feature. If no similar debt instrument exists, the Company estimates fair value by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities.
Revenue Recognition	Revenue Recognition— The Company records revenues primarily from product sales. These revenues are recorded net of rebates and other discounts. These rebates and discounts are estimated at the time of sale, and are largely driven by various customer program offerings, including special pricing agreements, promotions and other volume-based incentives. Rebates and discounts are calculated based upon historical experience, estimated discounting levels and estimated distributor inventory balances and recorded as a reduction of sales with offsets to accounts receivable and other current liabilities, respectively. Revenue is recognized when control of the products is transferred to the customers in an amount that reflects the consideration the Company expects to receive from the customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract and the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. A performance obligation is considered to be satisfied once the control of a product is transferred to the customer or the service is provided to the customer, meaning the customer has the ability to use and obtain the benefit of the goods or service. A portion of product sales includes revenues for diagnostic kits, which are utilized on leased instrument systems under the Company’s “reagent rental” program. The reagent rental program provides customers the right to use the instruments at no separate cost to the customer in consideration for a multi-year agreement to purchase annual minimum amounts of consumables (“reagents” or “diagnostic kits”). When an instrument is placed with a customer under a reagent rental agreement, the Company retains title to the equipment and it remains capitalized on the Company’s Consolidated Balance Sheets as property, plant and equipment, net. The instrument is depreciated on a straight-line basis over the lesser of the lease term or life of the instrument. Depreciation expense is recorded in cost of sales included in the Consolidated Statements of Income. Instrument and consumables under the reagent rental agreements are deemed two distinct performance obligations. Though the instrument and consumables do not have any use to customers without one another, they are not highly interdependent because they do not significantly affect each other. The Company would be able to fulfill its promise to transfer the instrument even if its customers did not purchase any consumables and the Company would be able to fulfill its promise to provide the consumables even if customers acquired instruments separately . The contract price is allocated between these two performance obligations based on the relative standalone selling prices. The instrument is considered an operating lease and revenue allocated to the instrument will be separately disclosed, if material.
Government Assistance	Government Assistance — During the year ended December 31, 2020, the Company entered into a contract with the National Institute of Health (“NIH”), through its newly launched Rapid Acceleration of Diagnostics - Advanced Technology Platforms initiative, to support the Company’s expansion of its manufacturing capacity for its diagnostic assays that test for the SARS-CoV-2 antigen. The contract provides for consideration to the Company of up to $65.0 million and has a performance period of one year, which began in July 2020. The contract includes key deliverables and milestones that will directly support the upgrade and addition of new manufacturing lines as well as the outfitting of a new distribution center. The Company will also provide instruments and assays to NIH. There are no refund provisions under the contract.
Research and Development Costs	Research and Development Costs— Research and development costs are charged to operations as incurred. In conjunction with certain third-party service agreements, the Company is required to make periodic payments based on achievement of certain milestones. The costs related to these research and development services are also charged to operations as incurred.
Product Shipment Costs	Product Shipment Costs—Product shipment costs are included in sales and marketing expense in the accompanying Consolidated Statements of Income.
Advertising Costs	Advertising Costs—Advertising costs are expensed as incurred.
Income Taxes	Income Taxes— Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of the income tax provision.
Fair Value of Financial Instruments	Fair Value of Financial Instruments — The Company uses the fair value hierarchy established in Accounting Standards Codification (“ASC”) Topic 820 , Fair Value Measurements and Disclosures, which requires that the valuation of assets and liabilities subject to fair value measurements be classified and disclosed by the Company in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts receivables, accounts payable and accrued liabilities approximate their fair values due to their short-term nature.
Stock-Based Compensation	Stock-Based Compensation—Compensation expense related to stock options granted is recognized ratably over the service vesting period for the entire option. For stock options with graded vesting, the Company ensures that the cumulative amount of compensation expense recognized at the end of any reporting period at least equals the portion of the stock option that has vested at that date. The total number of stock options expected to vest is adjusted by estimated forfeiture rates. The Company determined the estimated fair value of each stock option on the date of grant using the Black-Scholes option valuation model. The fair value of restricted stock units is determined based on the closing market price of the Company’s common stock on the grant date. Compensation expense for time-based restricted stock units (“RSUs”) is measured at the grant date and recognized ratably over the vesting period. A portion of the restricted stock granted are performance-based and vesting is tied to achievement of specific Company goals over a three-year time period, subject to early vesting upon achievement of the performance goals. For purposes of measuring compensation expense for performance-based restricted stock units (“PSUs”), the number of shares ultimately expected to vest is estimated at each reporting date based on management’s expectations regarding the relevant performance criteria. The grant date of the PSUs takes place when the grant is authorized and the specific achievement goals are communicated.
Comprehensive (Loss) Income	Comprehensive Income —Comprehensive income includes unrealized gains and losses which are related to the cumulative translation adjustments and derivative instruments excluded from the Company’s Consolidated Statements of Income.
Use of Estimates	Use of Estimates —The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Accounting Periods	Accounting Periods —Each of the Company’s fiscal quarters end on the Sunday closest to the end of the calendar quarter. The Company’s fiscal year ended January 3, 2021 was 53 weeks and the Company’s fiscal years ended December 29, 2019 and December 30, 2018 were 52 weeks. For ease of reference, the calendar year end dates are used herein.
Lessee, Operating Leases	Leases— Lease liabilities represent the obligation to make lease payments and right-of-use (“ROU”) assets represent the right to use the underlying asset during the lease term. Lease liabilities and ROU assets are recognized at the commencement date of the lease based on the present value of lease payments over the lease term at the commencement date. When the implicit rate is unknown, an incremental borrowing rate based on the information available at the commencement date is used in determining the present value of the lease payments. Options to extend or terminate the lease are included in the determination of the lease term when it is reasonably certain that the Company will exercise such options. For certain classes of assets, the Company accounts for lease and non-lease components as a single lease component. Variable lease payments, including those related to changes in the consumer price index, are recognized in the period in which the obligation for those payments are incurred and are not included in the measurement of the ROU assets or lease liabilities. Short-term leases are excluded from the calculation of the ROU assets and lease liabilities.

Earnings (Loss) Per Share Earni

Earnings (Loss) Per Share Earnings per share (Policies)	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Earnings Per Share, Policy [Policy Text Block]	Basic earnings per share (“EPS”) is computed by dividing net income by the weighted-average number of common shares outstanding. Diluted EPS is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of shares issuable from stock options, unvested RSUs and the 3.25% Convertible Senior Notes. Potentially dilutive common shares from outstanding stock options and unvested RSUs are determined using the average share price for each period under the treasury stock method. Potentially dilutive shares from the Convertible Senior Notes are determined using the if-converted method. Under the provisions of the if-converted method, the Convertible Senior Notes are assumed to be converted and the resulting common shares are included in the denominator of the EPS calculation and the interest expense, net of tax, recorded in connection with the Convertible Senior Notes is added back to net income. The Convertible Senior Notes have a dilutive impact when the average market price of the Company’s common stock exceeds the applicable conversion price of the notes. The Convertible Senior Notes became convertible on March 31, 2018 and matured on December 15, 2020.

Balance Sheet Account Details_2

Balance Sheet Account Details (Tables)	12 Months Ended
	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Schedule of Other Current Assets	The following is a summary of prepaid expenses and other current assets (in thousands): December 31, 2020 2019 Unbilled receivables $ 16,041 $ — Other receivables 15,442 7,857 Prepaid expenses 7,335 4,568 Other 2,157 4,445 Total prepaid expenses and other current assets $ 40,975 $ 16,870
Summary of Inventories	The following is a summary of inventories (in thousands): December 31, 2020 2019 Raw materials $ 58,264 $ 23,294 Work-in-process (materials, labor and overhead) 31,359 20,514 Finished goods (materials, labor and overhead) 24,175 14,278 Total inventories $ 113,798 $ 58,086
Property, Plant and Equipment	The following is a summary of property, plant and equipment (in thousands): December 31, 2020 2019 Equipment, furniture and fixtures $ 91,838 $ 80,599 Building and improvements 49,014 46,878 Leased instruments 60,722 47,656 Land 1,080 1,080 Construction in Progress 32,595 15,748 Total property, plant and equipment, gross 235,249 191,961 Less: accumulated depreciation and amortization (124,768) (112,199) Total property, plant and equipment, net $ 110,481 $ 79,762
Summary of Intangible Assets	Finite-lived intangible assets consisted of the following (dollar amounts in thousands): December 31, 2020 December 31, 2019 Description Weighted-average Gross Accumulated Net Gross Accumulated Net Purchased technology 9.1 $ 112,100 $ (71,426) $ 40,674 $ 112,100 $ (64,632) $ 47,468 Customer relationships 7.0 122,584 (60,688) 61,896 122,178 (44,045) 78,133 License agreements 9.9 6,518 (5,312) 1,206 6,509 (4,931) 1,578 Patent and trademark costs 10.8 28,740 (13,038) 15,702 28,740 (10,331) 18,409 Software development costs 5.0 8,743 (5,790) 2,953 7,432 (4,908) 2,524 Total finite-lived intangible assets $ 278,685 $ (156,254) $ 122,431 $ 276,959 $ (128,847) $ 148,112
Summary of Expected Future Annual Amortization Expense	The expected future annual amortization expense of the Company’s finite-lived intangible assets held as of December 31, 2020 is as follows (in thousands): For the years ending December 31, Amortization expense 2021 $ 27,452 2022 26,922 2023 26,211 2024 21,634 2025 7,979 Thereafter 12,233 Total $ 122,431
Schedule of Other Current Liabilities	The following is a summary of other current liabilities (in thousands): December 31, 2020 2019 Customer incentives $ 11,934 $ 7,369 Deferred revenue 3,733 336 Derivative liabilities 3,061 433 Other 13,562 6,724 Total other current liabilities $ 32,290 $ 14,862

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Summarized Interest Expense	The following table summarizes the amount of interest expense for the following periods (in thousands): Year ended December 31, 2020 2019 2018 Amortization of debt discount and deferred issuance costs $ 368 $ 1,179 $ 3,094 Coupon interest 195 1,103 2,992 Total Interest Expense $ 563 $ 2,282 $ 6,086
Schedule of Extinguishment of Debt	The following table summarizes information about the settlement of the Convertible Senior Notes during the year ended December 31, 2020 (dollars in thousands): Year ended December 31, 2020 Principal amount settled $ 13,131 Number of shares of common stock issued 225,955 Payment on Convertible Senior Note and Derivative Liability $ 43,446

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Components of (Benefit) Provision for Income Taxes	Significant components of the provision (benefit) for income taxes are as follows (in thousands): December 31, 2020 2019 2018 Current: Federal $ 198,498 $ 1,559 $ — State 34,608 746 755 Foreign 1,136 2,007 6,575 Total current provision 234,242 4,312 7,330 Deferred: Federal (2,855) 1,234 (9,970) State (1,104) (1,186) (7,944) Foreign (251) (103) (215) Total deferred (benefit) provision (4,210) (55) (18,129) Provision (benefit) for income taxes $ 230,032 $ 4,257 $ (10,799)
Schedule of Income before (Benefit) Provision for Income Taxes	The Company’s income before income taxes was subject to taxes in the following jurisdictions for the following periods (in thousands): December 31, 2020 2019 2018 United States $ 1,035,752 $ 70,606 $ 46,592 Foreign 4,567 6,572 16,792 Income before income taxes $ 1,040,319 $ 77,178 $ 63,384
Schedule of Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and deferred tax liabilities as of December 31, 2020 and 2019 are shown below (in thousands): December 31, 2020 2019 Deferred tax assets: Lease liability $ 24,790 $ 22,009 Intangible assets 2,747 3,951 Allowance for returns and discounts 27,277 5,266 Stock-based compensation 8,367 5,197 Tax credit carryforwards 11,770 13,846 Other, net 10,426 6,610 Total deferred tax assets 85,377 56,879 Valuation allowance for deferred tax assets (2,281) (2,353) Total deferred tax assets, net of valuation allowance 83,096 54,526 Deferred tax liabilities: Right-of-use assets (22,969) (20,334) Intangible assets (1,133) (1,633) Property, plant and equipment (14,232) (8,057) Total deferred tax liabilities (38,334) (30,024) Net deferred tax assets $ 44,762 $ 24,502
Reconciliation of Income Tax Computed at Federal Statutory Rate	The reconciliation of income tax computed at the federal statutory rate to the provision (benefit) for income taxes from continuing operations is as follows (in thousands): Year ended December 31, 2020 2019 2018 Tax expense at statutory tax rate $ 218,467 $ 16,207 $ 13,311 State tax expense, net of federal tax 30,289 1,061 1,526 Permanent differences 3,843 611 635 Federal and state research credits—current year (5,037) (4,269) (3,628) Stock-based compensation (13,867) (10,408) (9,286) Change in valuation allowance (72) 523 (13,374) Foreign Derived Intangible Income Deduction (FDII) (8,589) (159) (786) Other 4,998 691 803 Provision (benefit) for income taxes $ 230,032 $ 4,257 $ (10,799)
Summary of Unrecognized Tax Benefits	The following table summarizes the activity related to the Company’s unrecognized tax benefits (in thousands): Year ended December 31, 2020 2019 2018 Beginning balance $ 17,236 $ 15,245 $ 9,565 (Decreases) increases related to prior year tax positions (2,351) 287 (558) Increases related to current year tax positions 7,726 2,209 6,238 Expiration of the statute of limitations for the assessment of taxes (54) (505) — Ending balance $ 22,557 $ 17,236 $ 15,245

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Compensation Expense Related to Stock-Based Compensation Plans	Stock-based compensation expense was as follows (in thousands): Year ended December 31, 2020 2019 2018 Cost of sales $ 2,012 $ 1,162 $ 763 Research and development 3,372 2,332 2,266 Sales and marketing 6,009 3,497 2,843 General and administrative 9,626 6,261 5,837 Total stock-based compensation expense $ 21,019 $ 13,252 $ 11,709
Estimated Fair Value of Each Stock Option Award	The estimated fair value of each stock option was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions: Year ended December 31, 2020 2019 2018 Risk-free interest rate 1.18 % 2.51 % 2.49 % Expected option life (in years) 5.12 5.68 6.29 Volatility rate 41 % 39 % 36 % Dividend rate 0 % 0 % 0 %
Summary of Status of Stock Option Activity	A summary of the status of stock option activity for the years ended December 31, 2018, 2019 and 2020 is as follows (in thousands, except price data and years): Number Weighted- Weighted- Aggregate Outstanding at December 31, 2017 2,659 $ 18.54 Granted 159 46.50 Exercised (891) 17.07 Forfeited (50) 21.19 Outstanding at December 31, 2018 1,877 21.53 Granted 169 59.18 Exercised (1,091) 19.22 Forfeited (11) 49.71 Outstanding at December 31, 2019 944 30.63 Granted 145 96.34 Exercised (317) 21.03 Forfeited (12) 43.34 Outstanding at December 31, 2020 760 $ 46.95 6.79 $ 101,535 Vested and expected to vest at December 31, 2020 739 $ 46.03 6.74 $ 99,456 Exercisable at December 31, 2020 327 $ 23.32 5.16 $ 51,062
Summary of Status of Stock Awards Activity	A summary of the status of restricted stock unit activity for the years ended December 31, 2018, 2019 and 2020 is as follows (in thousands, except price data): Shares Weighted-average Non-vested at December 31, 2017 746 $ 20.88 Granted 242 49.97 Vested (296) 21.70 Forfeited (16) 28.40 Non-vested at December 31, 2018 676 30.75 Granted 279 59.75 Vested (148) 24.26 Forfeited (21) 43.90 Non-vested at December 31, 2019 786 41.88 Granted 235 101.20 Vested (123) 26.58 Forfeited (20) 58.32 Non-vested at December 31, 2020 878 $ 59.60

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following table reconciles net income and the weighted-average shares used in computing basic and diluted EPS in the respective periods (in thousands): Year ended December 31, 2020 2019 2018 Numerator: Net income used for basic earnings per share $ 810,287 $ 72,921 $ 74,183 Interest expense on Convertible Senior Notes, net of tax 445 1,848 4,927 Net income used for diluted earnings per share, if-converted method $ 810,732 $ 74,769 $ 79,110 Basic weighted-average common shares outstanding 42,124 40,860 37,995 Dilutive potential shares issuable from Convertible Senior Notes 295 1,062 2,850 Dilutive potential shares issuable from stock options and unvested RSUs 1,172 1,189 1,709 Diluted weighted-average common shares outstanding, if-converted 43,591 43,111 42,554 Potentially dilutive shares excluded from calculation due to anti-dilutive effect 10 199 161
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table reconciles net income and the weighted-average shares used in computing basic and diluted EPS in the respective periods (in thousands): Year ended December 31, 2020 2019 2018 Numerator: Net income used for basic earnings per share $ 810,287 $ 72,921 $ 74,183 Interest expense on Convertible Senior Notes, net of tax 445 1,848 4,927 Net income used for diluted earnings per share, if-converted method $ 810,732 $ 74,769 $ 79,110 Basic weighted-average common shares outstanding 42,124 40,860 37,995 Dilutive potential shares issuable from Convertible Senior Notes 295 1,062 2,850 Dilutive potential shares issuable from stock options and unvested RSUs 1,172 1,189 1,709 Diluted weighted-average common shares outstanding, if-converted 43,591 43,111 42,554 Potentially dilutive shares excluded from calculation due to anti-dilutive effect 10 199 161

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Components of Lease Expense and Supplemental Cash Flow Information	The components of lease expense and supplemental cash flow information related to leases during the respective periods are as follows (in thousands): Year ended December 31, 2020 2019 Finance lease ROU asset amortization $ 303 $ 314 Finance lease interest expense 877 835 Total finance lease costs 1,180 1,149 Operating lease costs 11,236 10,130 Total lease costs $ 12,416 $ 11,279 Cash paid for amounts included in the measurement of operating lease liabilities Operating cash flows from operating leases $ 10,801 $ 9,385 Operating cash flows from finance leases $ 877 $ 835 ROU assets obtained in exchange for new lease liabilities Operating leases $ 15,271 $ 12,231 Finance leases $ — $ 1,369
Commitments for Minimum Rentals under Non-cancelable Operating Leases	The Company leases its facilities and certain equipment. Commitments for minimum rentals under non-cancelable leases at the end of 2020 are as follows (dollars in thousands): Years ending December 31, Operating Finance 2021 $ 12,043 $ 1,215 2022 11,396 1,258 2023 11,281 1,277 2024 11,226 1,098 2025 11,327 1,019 Thereafter 79,893 12,420 Total lease payments 137,166 18,287 Less: imputed interest (28,661) (13,949) Total 108,505 4,338 Less: current portion (7,799) (238) Non-current portion $ 100,706 $ 4,100 Weighted average remaining lease term 14.3 years 12.6 years Weighted average discount rate 4 % 27 %
Commitments for Minimum Rentals under Non-cancelable Finance Leases	The Company leases its facilities and certain equipment. Commitments for minimum rentals under non-cancelable leases at the end of 2020 are as follows (dollars in thousands): Years ending December 31, Operating Finance 2021 $ 12,043 $ 1,215 2022 11,396 1,258 2023 11,281 1,277 2024 11,226 1,098 2025 11,327 1,019 Thereafter 79,893 12,420 Total lease payments 137,166 18,287 Less: imputed interest (28,661) (13,949) Total 108,505 4,338 Less: current portion (7,799) (238) Non-current portion $ 100,706 $ 4,100 Weighted average remaining lease term 14.3 years 12.6 years Weighted average discount rate 4 % 27 %

Industry and Geographic Infor_2

Industry and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Sales to Individual Customers in Excess of 10% of Total Revenue	The Company had sales to individual customers in excess of 10% of total revenue, as follows: Year ended December 31, 2020 2019 2018 Customer: A 29 % 13 % 12 % B 16 % 18 % 19 % C 13 % 5 % 5 % D 10 % 15 % 13 % 68 % 51 % 49 %
Long-Lived Assets (Excluding Intangible Assets) and Total Net Revenue	The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory (in thousands): Long-lived assets as of December 31, Total revenue 2020 2019 2020 2019 2018 Domestic $ 108,375 $ 78,254 $ 1,452,329 $ 358,381 $ 354,895 Foreign 2,106 1,508 209,339 176,509 167,390 Total $ 110,481 $ 79,762 $ 1,661,668 $ 534,890 $ 522,285
Consolidated Net Product Revenues by Disease State	Consolidated total revenues by product category are as follows (in thousands): Year ended December 31, 2020 2019 2018 Rapid Immunoassay $ 1,144,831 $ 191,736 $ 183,160 Cardiometabolic Immunoassay 242,933 266,505 266,524 Molecular Diagnostic Solutions 222,964 21,716 19,358 Specialized Diagnostic Solutions 50,940 54,933 53,243 Total revenues $ 1,661,668 $ 534,890 $ 522,285

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents the Company’s hierarchy for its assets and liabilities measured at fair value on a recurring basis as of the following periods (in thousands): December 31, 2020 December 31, 2019 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Cash equivalents (money market funds) $ 200,003 $ — $ — $ 200,003 $ — $ — $ — $ — Derivative assets — 24 — 24 — 321 — 321 Total assets measured at fair value $ 200,003 $ 24 $ — $ 200,027 $ 321 $ — $ 321 Liabilities: Derivative liabilities $ — $ 3,061 $ — $ 3,061 $ — $ 433 $ — $ 433 Contingent consideration — — 11,896 11,896 — — 16,535 16,535 Deferred consideration — 115,951 — 115,951 — 151,382 — 151,382 Total liabilities measured at fair value $ — $ 119,012 $ 11,896 $ 130,908 $ — $ 151,815 $ 16,535 $ 168,350
Changes in Estimated Fair Value of Contingent Consideration Liabilities	Changes in estimated fair value of contingent consideration liabilities from December 31, 2017 through December 31, 2020 are as follows (in thousands): Contingent consideration Balance at December 31, 2017 $ 24,301 Cash payments (6,303) Change in estimated fair value, recorded in general and administrative expenses 1,114 Balance at December 31, 2018 19,112 Cash payments (4,044) Change in estimated fair value, recorded in general and administrative expenses 1,467 Balance at December 31, 2019 16,535 Cash payments (6,044) Change in estimated fair value, recorded in general and administrative expenses 1,405 Balance at December 31, 2020 $ 11,896

Derivatives and Hedging (Tables

Derivatives and Hedging (Tables)	12 Months Ended
	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Assets at Fair Value [Table Text Block]	The following table summarizes the fair value and notional amounts of the foreign currency forward contracts as of December 31, 2020 and December 31, 2019 (in thousands): December 31, 2020 December 31, 2019 Notional Amount Fair Value, Net Notional Amount Fair Value, Net Designated cash flow hedges: Prepaid expenses and other current assets $ — $ — $ 27,944 $ 321 Other current liabilities $ 38,435 $ 2,819 $ 6,219 $ 433 Non-designated forward contracts: Prepaid expenses and other current assets $ 18,160 $ 24 $ — $ — Other current liabilities $ 23,120 $ 242 $ — $ —

Selected Quarterly Financial _2

Selected Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data	First Quarter Second Quarter Third Quarter Fourth Quarter (in thousands, except per share data) 2020 Total revenues $ 174,653 $ 201,754 $ 476,058 $ 809,203 Gross profit $ 114,991 $ 148,751 $ 383,619 $ 701,494 Operating income $ 51,628 $ 83,663 $ 307,959 $ 617,076 Net income $ 40,237 $ 67,652 $ 232,268 $ 470,130 Basic income per share $ 0.96 $ 1.61 $ 5.52 $ 11.14 Diluted income per share $ 0.93 $ 1.55 $ 5.33 $ 10.78 2019 Total revenues $ 147,968 $ 108,252 $ 126,492 $ 152,178 Gross profit $ 90,927 $ 59,179 $ 75,859 $ 94,840 Operating income $ 31,153 $ 5,818 $ 20,682 $ 35,063 Net income $ 24,844 $ 1,270 $ 16,181 $ 30,626 Basic earnings per share $ 0.63 $ 0.03 $ 0.39 $ 0.73 Diluted earnings per share $ 0.60 $ 0.03 $ 0.38 $ 0.71

Company Operations and Summar_3

Company Operations and Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)segment	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of reportable segments | segment	1
Cash and cash equivalents maximum maturity period	3 months
Allowance receivables	$ 103,400	$ 16,000
Allowance receivables, contract rebates	100,800	15,700
Costs and Expenses	288,529	228,089	$ 219,784
Contract Consideration	65,000
Government Contract Receivable	15,900
Unbilled Contracts Receivable	$ 16,041	0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of the assets	3 years
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of the assets	15 years
Shipping and Handling [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Costs and Expenses	$ 14,200	9,500	8,300
Advertising [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Costs and Expenses	$ 1,100	$ 1,300	$ 900

Balance Sheet Account Details -

Balance Sheet Account Details - Prepaid expenses and other current assets (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Offsetting [Abstract]
Unbilled Contracts Receivable	$ 16,041	$ 0
Receivables under transition service agreements	15,442	7,857
Prepaid expenses	7,335	4,568
Other	2,157	4,445
Prepaid expenses and other current assets	$ 40,975	$ 16,870

Balance Sheet Account Details_3

Balance Sheet Account Details - Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 58,264	$ 23,294
Work-in-process (materials, labor and overhead)	31,359	20,514
Finished goods (materials, labor and overhead)	24,175	14,278
Total inventories	$ 113,798	$ 58,086

Balance Sheet Account Details_4

Balance Sheet Account Details - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	$ 235,249	$ 191,961
Less: accumulated depreciation and amortization	(124,768)	(112,199)
Property, Plant and Equipment, Net	110,481	79,762
Depreciation and amortization	20,800	19,400	$ 17,700
Equipment, furniture and fixtures
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	91,838	80,599
Building and improvements
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	49,014	46,878
Leased instruments
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	60,722	47,656
Land
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	1,080	1,080
Construction in Progress
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	$ 32,595	$ 15,748

Balance Sheet Account Details_5

Balance Sheet Account Details - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Depreciation and amortization	$ 20,800	$ 19,400	$ 17,700
Amortization of Intangible Assets	27,300	27,500	28,800
Goodwill	337,032	337,018
Capitalized Software Cost [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 900	$ 800	$ 1,000

Balance Sheet Account Details_6

Balance Sheet Account Details - Goodwill and Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Gross assets	$ 278,685	$ 276,959
Accumulated amortization	(156,254)	(128,847)
Total	$ 122,431	148,112
Purchased technology
Finite-Lived Intangible Assets [Line Items]
Weighted-average useful life (years)	9 years 1 month 6 days
Gross assets	$ 112,100	112,100
Accumulated amortization	(71,426)	(64,632)
Total	$ 40,674	47,468
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted-average useful life (years)	7 years
Gross assets	$ 122,584	122,178
Accumulated amortization	(60,688)	(44,045)
Total	$ 61,896	78,133
License agreements
Finite-Lived Intangible Assets [Line Items]
Weighted-average useful life (years)	9 years 10 months 24 days
Gross assets	$ 6,518	6,509
Accumulated amortization	(5,312)	(4,931)
Total	$ 1,206	1,578
Patent and trademark costs
Finite-Lived Intangible Assets [Line Items]
Weighted-average useful life (years)	10 years 9 months 18 days
Gross assets	$ 28,740	28,740
Accumulated amortization	(13,038)	(10,331)
Total	$ 15,702	18,409
Software development costs
Finite-Lived Intangible Assets [Line Items]
Weighted-average useful life (years)	5 years
Gross assets	$ 8,743	7,432
Accumulated amortization	(5,790)	(4,908)
Total	$ 2,953	$ 2,524

Balance Sheet Account Details_7

Balance Sheet Account Details - Future annual amortization expense (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]
2018	$ 27,452
2019	26,922
2020	26,211
2021	21,634
2022	7,979
Thereafter	12,233
Total	$ 122,431	$ 148,112

Balance Sheet Account Details_8

Balance Sheet Account Details - Other current liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Offsetting [Abstract]
Customer incentives	$ 11,934	$ 7,369
Deferred revenue	3,733	336
Derivative liabilities	3,061	433
Other	13,562	6,724
Total other current liabilities	$ 32,290	$ 14,862

Debt - Convertible Senior Notes

Debt - Convertible Senior Notes (Details) - Convertible Debt - USD ($)	Dec. 31, 2020	Dec. 31, 2015
Debt Instrument [Line Items]
Convertible Senior Notes, face amount		$ 172,500,000
3.25% Convertible Senior Notes due 2020 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage		6.90%
Convertible Senior Notes, fair value disclosures		$ 141,900,000
Debt Instrument, Convertible, Carrying Amount of Equity Component		$ 30,700,000
Convertible Debt | 3.25% Convertible Senior Notes due 2020 [Member]
Debt Instrument [Line Items]
Senior Credit Facility, applicable margin	3.25%

Debt - Summarized Interest Expe

Debt - Summarized Interest Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Total Interest Expense	$ 563	$ 2,282	$ 6,086
Convertible Debt | 3.25% Convertible Senior Notes due 2020 [Member]
Debt Instrument [Line Items]
Amortization of debt discount and deferred issuance costs	368	1,179	3,094
Coupon interest	$ 195	$ 1,103	$ 2,992

Debt - Schedule of Extinguishme

Debt - Schedule of Extinguishment of Debt (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Extinguishment of Debt [Line Items]
Payment on Convertible Senior Note and Derivative Liability	$ 43,446	$ 0	$ 0
Convertible Debt
Extinguishment of Debt [Line Items]
Number of shares of common stock issued	225,955	1,497,000	3,699,000
Payment on Convertible Senior Note and Derivative Liability	$ 43,446
Convertible Debt | Convertible Debt
Extinguishment of Debt [Line Items]
Principal amount settled	$ 13,131

Debt - Credit Agreement (Detail

Debt - Credit Agreement (Details) - USD ($)	Aug. 31, 2018	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 175,000,000
Line of Credit Facility, Commitment Fee Percentage	0.15%
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.30%
Number Of Financial Covenants	2
Consolidated Leverage Ratio	3.50
Consolidated Fixed Charge Coverage Ratio	1.25
Total Interest Expense		$ 563,000	$ 2,282,000	$ 6,086,000
Fed Funds Effective Rate Overnight Index Swap Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		0.005%
Minimum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Senior Credit Facility, applicable margin	0.75%
Minimum [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Senior Credit Facility, applicable margin	1.75%
Maximum [Member]
Debt Instrument [Line Items]
Consolidated Leverage Ratio	4.50
Maximum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Senior Credit Facility, applicable margin	1.50%
Maximum [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Senior Credit Facility, applicable margin	2.50%
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Term		5 years
Total Interest Expense		$ 700,000	$ 1,700,000	$ 6,500,000

Income Taxes - Components of (B

Income Taxes - Components of (Benefit) Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Current:
Federal	$ 198,498	$ 1,559	$ 0
State	34,608	746	755
Foreign	1,136	2,007	6,575
Total current provision	234,242	4,312	7,330
Deferred:
Federal	(2,855)	1,234	(9,970)
State	(1,104)	(1,186)	(7,944)
Foreign	(251)	(103)	(215)
Total deferred (benefit) provision	(4,210)	(55)	(18,129)
Provision (benefit) for income taxes	230,032	4,257	(10,799)
Accrued interest and penalties associated with uncertain tax positions	$ 500	$ 400	$ 300

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income before (Benefit) Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
United States	$ 1,035,752	$ 70,606	$ 46,592
Foreign	4,567	6,572	16,792
Income before income taxes	$ 1,040,319	$ 77,178	$ 63,384

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Lease liability	$ 24,790	$ 22,009
Intangible assets	2,747	3,951
Allowance for returns and discounts	27,277	5,266
Stock-based compensation	8,367	5,197
Tax credit carryforwards	11,770	13,846
Other, net	10,426	6,610
Total deferred tax assets	85,377	56,879
Valuation allowance for deferred tax assets	(2,281)	(2,353)
Total deferred tax assets	83,096	54,526
Deferred tax liabilities:
Right-of-use assets	(22,969)	(20,334)
Intangible assets	(1,133)	(1,633)
Property, plant and equipment	(14,232)	(8,057)
Deferred Tax Liabilities, Gross	(38,334)	(30,024)
Net deferred tax assets	$ 44,762	$ 24,502

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Taxes Disclosure [Line Items]
Increase (decrease) in valuation allowance	$ (100,000)
Deferred Tax Assets, Valuation Allowance	2,281,000	$ 2,353,000
Unrecognized Tax Benefits	22,557,000	17,236,000	$ 15,245,000	$ 9,565,000
Federal Net Operating Loss carryforwards	0
State Net Operating Loss carryforwards	5,900,000
Federal foreign tax credits	2,300,000
Gross research credits	$ 5,037,000	4,269,000	3,628,000
Cumulative changes in ownership percentage	50.00%
Cumulative Change In Ownership Period	3 years
Realized upon settlement	50.00%
Unrecognized tax benefits that would impact effective tax rate	$ 15,000,000	11,100,000	9,300,000
Accrued interest and penalties associated with uncertain tax positions	500,000	400,000	300,000
Interest expense, net of accrued interest reversed	100,000	$ 100,000	$ 100,000
Federal research credits [Member]
Income Taxes Disclosure [Line Items]
Federal research credits	0
Gross State Research Credits [Member]
Income Taxes Disclosure [Line Items]
State research credit - no expiry	$ 12,300,000

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Income Tax Computed at Federal Statutory Rate (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Tax expense at statutory tax rate	$ 218,467	$ 16,207	$ 13,311
State tax expense, net of federal tax	30,289	1,061	1,526
Permanent differences	3,843	611	635
Federal and state research credits—current year	(5,037)	(4,269)	(3,628)
Stock-based compensation	(13,867)	(10,408)	(9,286)
Change in valuation allowance	(72)	523	(13,374)
Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount	(8,589)	(159)	(786)
Other	4,998	691	803
Provision (benefit) for income taxes	$ 230,032	$ 4,257	$ (10,799)

Income Taxes - Summary of Unrec

Income Taxes - Summary of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning balance	$ 17,236	$ 15,245	$ 9,565
Decreases related to prior year tax positions	(2,351)		(558)
Increases related to prior year tax positions		287
Increases related to current year tax positions	7,726	2,209	6,238
Expiration of the statute of limitations for the assessment of taxes	(54)	(505)	0
Ending balance	$ 22,557	$ 17,236	$ 15,245

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Aug. 28, 2020	Dec. 12, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares outstanding	0	0
Weighted- average remaining contractual term, exercisable (in years)	5 years 1 month 28 days
Available for future grant, (in shares)	2,200,000
Common Stock, Capital Shares Reserved for Future Issuance	3,800,000
Restricted stock granted (in shares)	235,000	279,000	242,000
Share-based compensation expense recognized	$ 21,019	$ 13,252	$ 11,709
Deferred period of grants (Condition 1)	1 year
Percentage of premium on amount deferred (Condition 1)	10.00%
Deferred period of grants (Condition 2)	2 years
Percentage of premium on amount deferred (Condition 2)	20.00%
Length Of Time Of Deferral Period Under Condition Three	4 years
Percentage of premium on amount deferred (Condition 3)	30.00%
Minimum percentage of common stock under payroll deductions	10.00%
Fair value of payroll deductions	85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Period	6 months
Capital shares reserved for future issuance (In shares)	86,571
Payments for repurchase of common stock	$ 47,889	10,728	4,344
Stock-based compensation expense	$ 47,889	$ 10,728	$ 4,344
Authorized stock repurchase program amount				$ 150,000	$ 50,000
Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased	156,300,000
Stock Repurchased During Period, Shares	257,329
Restricted stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted- average remaining contractual term, exercisable (in years)	10 years
Performance-based vesting period	4 years
Restricted stock granted (in shares)	200,000	300,000	200,000
Employee Deferred Bonus Compensation Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	$ 2,200	$ 1,400	$ 1,600
Non-employee director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	$ 500	$ 500	$ 400
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in usd per share)	$ 14.56
Percentage of deferred cash bonus	50.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in usd per share)	$ 248.41
Percentage of deferred cash bonus	100.00%

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	$ 21,019	$ 13,252	$ 11,709
Weighted-average grant date fair value of stock options granted (in dollars per share)	$ 36.84	$ 23.67	$ 18.76
Total intrinsic value for options exercised	$ 51,800	$ 49,800	$ 38,200
Total unrecognized compensation expense related to non-vested stock options	$ 7,100
Expected weighted-average period of recognition for unrecognized compensation expense	2 years
Maximum contractual term	10 years
Deferred bonus compensation program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	$ 2,200	1,400	1,600
Recorded as a component of accrued payroll and related expenses	$ 2,100	$ 800	$ 1,600
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period of recognition for unrecognized compensation expense	1 year 4 months 24 days
Restricted stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation expense related to non-vested stock awards	$ 25,200

Stock-Based Compensation - Comp

Stock-Based Compensation - Compensation Expense Related to Stock-Based Compensation Plans (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 21,019	$ 13,252	$ 11,709
Cost of sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	2,012	1,162	763
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	3,372	2,332	2,266
Sales and marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	6,009	3,497	2,843
General and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 9,626	$ 6,261	$ 5,837

Stock-Based Compensation - Esti

Stock-Based Compensation - Estimated Fair Value of Each Stock Option Award (Detail)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Equity [Abstract]
Risk-free interest rate	1.18%	2.51%	2.49%
Expected option life (in years)	5 years 1 month 13 days	5 years 8 months 4 days	6 years 3 months 14 days
Volatility rate	41.00%	39.00%	36.00%
Dividend rate	0.00%	0.00%	0.00%

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Status of Stock Option Activity (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Number of Shares
Beginning balance, (in shares)	944	1,877	2,659
Granted, number of shares (in shares)	145	169	159
Exercised (in shares)	(317)	(1,091)	(891)
Forfeited (in shares)	(12)	(11)	(50)
Ending balance, (in shares)	760	944	1,877
Vested and expected to vest, (in shares)	739
Exercisable, (in shares)	327
Weighted- average exercise price per share
Beginning balance (in dollars per share)	$ 30.63	$ 21.53	$ 18.54
Granted (in dollars per share)	96.34	59.18	46.50
Exercised (in dollars per share)	21.03	19.22	17.07
Forfeited (in dollars per share)	43.34	49.71	21.19
Ending balance (in dollars per share)	46.95	$ 30.63	$ 21.53
Vested and expected to vest (in dollars per share)	46.03
Exercisable (in dollars per share)	$ 23.32
Weighted-average remaining contractual term (in years) and Aggregate intrinsic value
Weighted- average remaining contractual term, outstanding (in years)	6 years 9 months 14 days
Weighted- average remaining contractual term, vested and expected to vest (in years)	6 years 8 months 26 days
Weighted- average remaining contractual term, exercisable (in years)	5 years 1 month 28 days
Aggregate intrinsic value, outstanding	$ 101,535
Aggregate intrinsic value, vested and expected to vest	99,456
Aggregate intrinsic value, available for future grant	$ 51,062

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Status of Stock Awards Activity (Detail) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Payment Arrangement [Abstract]
Granted (in dollars per share)	$ 96.34	$ 59.18	$ 46.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Beginning Balance (in shares)	786	676	746
Granted (in shares)	235	279	242
Vested (in shares)	(123)	(148)	(296)
Forfeited (in shares)	(20)	(21)	(16)
Ending Balance (in shares)	878	786	676
Weighted- average exercise price per share
Beginning Balance, Weighted Average Grant Date Fair Value (in dollars per share)	$ 41.88	$ 30.75	$ 20.88
Granted, Weighted Average Grant Date Fair Value (in dollars per share)	101.20	59.75	49.97
Exercised (in dollars per share)	21.03	19.22	17.07
Vested, Weighted Average Grant Date Fair Value (in dollars per share)	26.58	24.26	21.70
Forfeited (in dollars per share)	43.34	49.71	21.19
Forfeited, Weighted Average Grant Date Fair Value (in dollars per share)	58.32	43.90	28.40
Ending Balance, Weighted Average Grant Date Fair Value (in dollars per share)	$ 59.60	$ 41.88	$ 30.75

Earnings (Loss) Per Share Compu

Earnings (Loss) Per Share Computation of earnings per share (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net Income (Loss) Attributable to Parent	$ 470,130	$ 232,268	$ 67,652	$ 40,237	$ 30,626	$ 16,181	$ 1,270	$ 24,844	$ 810,287	$ 72,921	$ 74,183
Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities									445	1,848	4,927
Net Income (Loss) Available to Common Stockholders, Diluted									$ 810,732	$ 74,769	$ 79,110
Basic weighted-average common shares outstanding									42,124	40,860	37,995
Dilutive potential shares issuable from Convertible Senior Notes									295	1,062	2,850
Dilutive potential shares issuable from stock options and unvested RSUs									1,172	1,189	1,709
Shares used in diluted per share calculation									43,591	43,111	42,554
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount									10	199	161
Retained earnings [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net Income (Loss) Attributable to Parent									$ 810,287	$ 72,921	$ 74,183
3.25% Convertible Senior Notes due 2020 [Member] | Convertible Debt | Convertible Debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Senior Credit Facility, applicable margin	3.25%								3.25%

Earnings (Loss) Per Share Weigh

Earnings (Loss) Per Share Weighted-average shares outstanding (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Basic weighted-average common shares outstanding	42,124	40,860	37,995
Dilutive potential shares issuable from Convertible Senior Notes	295	1,062	2,850
Dilutive potential shares issuable from stock options and unvested RSUs	1,172	1,189	1,709
Diluted weighted-average common shares outstanding, if-converted	43,591	43,111	42,554
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	10	199	161

Commitments and Contingencies -

Commitments and Contingencies - Components of Lease Expense and Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Finance Lease, Right-of-Use Asset, Amortization	$ 303	$ 314
Finance Lease, Interest Expense	877	835
Finance Lease, Cost	1,180	1,149
Operating Lease, Cost	11,236	10,130
Lease, Cost	12,416	11,279
Operating Lease, Payments	10,801	9,385
Finance Lease, Interest Payment on Liability	877	835
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	15,271	12,231
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	$ 0	$ 1,369

Commitments and Contingencies_2

Commitments and Contingencies - Commitments for Minimum Rentals under Non-cancelable Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Operating Leases, 2020	$ 12,043
Operating Leases, 2021	11,396
Operating Leases, 2022	11,281
Operating Leases, 2023	11,226
Operating Leases, 2024	11,327
Operating Leases, Thereafter	79,893
Operating Leases, Minimum Payments, Total	137,166
Lease Obligation, 2020	1,215
Lease Obligation, 2021	1,258
Lease Obligation, 2022	1,277
Lease Obligation, 2023	1,098
Lease Obligation, 2024	1,019
Lease Obligation, Thereafter	12,420
Lease Obligation, Minimum Payments, Total	18,287
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	28,661
Finance Lease, Liability, Undiscounted Excess Amount	13,949
Operating Lease, Liability	108,505
Finance Lease, Liability	4,338
Operating Lease, Liability, Current	(7,799)	$ (6,412)
Finance Lease, Liability, Current	(238)
Operating lease liabilities - non-current	100,706	93,227
Finance Lease, Liability, Noncurrent	$ 4,100
Operating Lease, Weighted Average Remaining Lease Term	14 years 3 months 18 days
Finance Lease, Weighted Average Remaining Lease Term	12 years 7 months 6 days
Operating Lease, Weighted Average Discount Rate, Percent	4.00%
Finance Lease, Weighted Average Discount Rate, Percent	27.00%
Right-of-use assets	$ 100,544	$ 92,119

Commitments and Contingencies_3

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)optionbuilding	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Other Commitments [Line Items]
Number of buildings leased | building	3
Number of buildings | building	4
Number of additional terms to extend the lease | option	2
Renewal term	5 years
Minimum lease payments	$ 137,166
Purchase commitment	32,100
Royalty Expense	2,400	$ 1,100	$ 400
Rutherford [Member]
Other Commitments [Line Items]
Minimum lease payments	$ 70,500
Partnership, McKellar San Diego Facility
Other Commitments [Line Items]
Partnership that acquired the facility	25.00%
Lease payments	$ 1,000	$ 1,000	$ 900

Commitments and Contingencies C

Commitments and Contingencies Contingent Consideration (Acquisitions) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition, Contingent Consideration [Line Items]
Current portion of contingent consideration	$ 5,987	$ 5,969
Contingent consideration non-current portion	5,909	10,566
Fair Value, Inputs, Level 3 [Member]
Business Acquisition, Contingent Consideration [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	$ 1,405	$ 1,467	$ 1,114

Industry and Geographic Infor_3

Industry and Geographic Information - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2020USD ($)segment	Dec. 31, 2019USD ($)	Dec. 31, 2018
Revenue, Major Customer [Line Items]
Number of reportable segments | segment	1
Customer Concentration Risk [Member] | Sales [Member]
Revenue, Major Customer [Line Items]
Percentage of risk concentration by major customer	68.00%	51.00%	49.00%
Customer Concentration Risk [Member] | Sales [Member] | Non-US [Member]
Revenue, Major Customer [Line Items]
Percentage of risk concentration by major customer	13.00%	33.00%	32.00%
Customer Concentration Risk [Member] | Sales [Member] | CHINA
Revenue, Major Customer [Line Items]
Percentage of risk concentration by major customer	4.00%	13.00%	10.00%
Geographic Concentration Risk [Member] | Non-US [Member]
Revenue, Major Customer [Line Items]
Accounts receivable	$ 18.6	$ 22.9
Product Concentration Risk [Member] | Sales [Member]
Revenue, Major Customer [Line Items]
Percentage of risk concentration by major customer	8.00%	26.00%	24.00%
Credit Concentration Risk [Member]
Revenue, Major Customer [Line Items]
Accounts receivable	$ 411.7	$ 53.5
Coronavirus [Member] | Sales [Member]
Revenue, Major Customer [Line Items]
Percentage of risk concentration by major customer	70.00%

Industry and Geographic Infor_4

Industry and Geographic Information - Sales to Individual Customers in Excess of 10% of Total Revenue (Detail) - Sales [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenue, Major Customer [Line Items]
Sales percentage	68.00%	51.00%	49.00%
A
Revenue, Major Customer [Line Items]
Sales percentage	29.00%	13.00%	12.00%
B
Revenue, Major Customer [Line Items]
Sales percentage	16.00%	18.00%	19.00%
C
Revenue, Major Customer [Line Items]
Sales percentage	13.00%	5.00%	5.00%
D
Revenue, Major Customer [Line Items]
Sales percentage	10.00%	15.00%	13.00%

Industry and Geographic Infor_5

Industry and Geographic Information - Long-lived Assets (Excluding Intangible Assets) and Total Net Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, Total	$ 110,481				$ 79,762				$ 110,481	$ 79,762
Revenue from Contract with Customer, Including Assessed Tax	809,203	$ 476,058	$ 201,754	$ 174,653	152,178	$ 126,492	$ 108,252	$ 147,968	1,661,668	534,890	$ 522,285
Federal [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, Total	108,375				78,254				108,375	78,254
Revenue from Contract with Customer, Including Assessed Tax									1,452,329	358,381	354,895
Foreign [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, Total	$ 2,106				$ 1,508				2,106	1,508
Revenue from Contract with Customer, Including Assessed Tax									$ 209,339	$ 176,509	$ 167,390

Industry and Geographic Infor_6

Industry and Geographic Information - Consolidated Net Product Revenues by Disease State (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting Information [Line Items]
Revenues	$ 1,661,668	$ 534,890	$ 522,285
Infectious Disease [Member]
Segment Reporting Information [Line Items]
Revenues	1,144,831	191,736	183,160
Cardiac Immunoassay [Member]
Segment Reporting Information [Line Items]
Revenues	242,933	266,505	266,524
Specialized Diagnostic Solutions [Member]
Segment Reporting Information [Line Items]
Revenues	50,940	54,933	53,243
Molecular Diagnostic Solutions [Member]
Segment Reporting Information [Line Items]
Revenues	$ 222,964	$ 21,716	$ 19,358

Fair Value Measurement - Assets

Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$ 130,908	$ 168,350
Assets, Fair Value Disclosure	200,027	321
Derivative liabilities	3,061	433
Derivative [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Asset	24
Derivative liabilities	3,061
Contingent consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	11,896	16,535
Deferred consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	115,951	151,382
Money Market Funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Deposits, Money Market Deposits	200,003
Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0
Assets, Fair Value Disclosure	200,003
Level 1 [Member] | Derivative [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Asset	0	0
Derivative liabilities	0	0
Level 1 [Member] | Contingent consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0
Level 1 [Member] | Deferred consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0
Level 1 [Member] | Money Market Funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Deposits, Money Market Deposits	200,003	0
Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	119,012	151,815
Assets, Fair Value Disclosure	24	321
Level 2 [Member] | Derivative [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Asset	24	321
Derivative liabilities	3,061	433
Level 2 [Member] | Contingent consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0
Level 2 [Member] | Deferred consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	115,951	151,382
Level 2 [Member] | Money Market Funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Deposits, Money Market Deposits	0	0
Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	11,896	16,535
Assets, Fair Value Disclosure	0	0
Level 3 [Member] | Derivative [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Asset	0	0
Derivative liabilities	0	0
Level 3 [Member] | Contingent consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	11,896	16,535
Level 3 [Member] | Deferred consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0
Level 3 [Member] | Money Market Funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Deposits, Money Market Deposits	$ 0	$ 0

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Accretion of interest on deferred consideration	$ 6,569	$ 8,224	$ 10,000
Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	1,405	$ 1,467	$ 1,114
Consideration B [Member] | BNP Business [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Amount Of Installment Payment	42,000
Consideration A [Member] | BNP Business [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Amount Of Installment Payment	$ 8,000

Fair Value Measurement - Change

Fair Value Measurement - Changes in Estimated Fair Value of Contingent Consideration Liabilities (Detail) - Level 3 [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 16,535	$ 19,112	$ 24,301
Cash payments	(6,044)	(4,044)	(6,303)
Change in estimated fair value, recorded in general and administrative expenses	(1,405)	(1,467)	(1,114)
Ending balance	$ 11,896	$ 16,535	$ 19,112

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Compensation Related Costs [Abstract]
Pay contributed by employer	50.00%
Pay contributed by employee	6.00%
Contribution to 401 (K) Plan	$ 3.1	$ 2.5	$ 2.6

Derivatives and Hedging (Detail

Derivatives and Hedging (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Cash Flow Hedging | Designated as Hedging Instrument
Derivative [Line Items]
Derivative Liability, Notional Amount	$ 38,435	$ 6,219
Derivative Liability, Fair Value, Gross Liability	2,819	433
Prepaid Expenses and Other Current Assets [Member]
Derivative [Line Items]
Derivative Asset, Notional Amount	0
Derivative, Fair Value, Net	0
Prepaid Expenses and Other Current Assets [Member] | Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative Asset, Notional Amount	18,160	0
Derivative Liability, Notional Amount	23,120	0
Derivative Asset, Fair Value, Gross Asset	24	0
Derivative Liability, Fair Value, Gross Liability	242	0
Prepaid Expenses and Other Current Assets [Member] | Cash Flow Hedging | Designated as Hedging Instrument
Derivative [Line Items]
Derivative Asset, Notional Amount	0	27,944
Derivative Asset, Fair Value, Gross Asset	0	$ 321
Other Current Liabilities [Member]
Derivative [Line Items]
Derivative Asset, Notional Amount	38,435
Derivative, Fair Value, Net	$ 2,819

Selected Quarterly Financial _3

Selected Quarterly Financial Data (unaudited) - Quarterly Financial Data (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Revenue from Contract with Customer, Including Assessed Tax	$ 809,203	$ 476,058	$ 201,754	$ 174,653	$ 152,178	$ 126,492	$ 108,252	$ 147,968	$ 1,661,668	$ 534,890	$ 522,285
Cost of Goods and Services Sold									312,813	214,085	206,572
Gross profit	701,494	383,619	148,751	114,991	94,840	75,859	59,179	90,927	1,348,855	320,805	315,713
Operating income	617,076	307,959	83,663	51,628	35,063	20,682	5,818	31,153	1,060,326	92,716	95,929
Net income	$ 470,130	$ 232,268	$ 67,652	$ 40,237	$ 30,626	$ 16,181	$ 1,270	$ 24,844	$ 810,287	$ 72,921	$ 74,183
Basic and diluted loss per share	$ 11.14	$ 5.52	$ 1.61	$ 0.96	$ 0.73	$ 0.39	$ 0.03	$ 0.63
Diluted net earnings (loss) per share	$ 10.78	$ 5.33	$ 1.55	$ 0.93	$ 0.71	$ 0.38	$ 0.03	$ 0.60	$ 18.60	$ 1.73	$ 1.86

Consolidated Valuation and Qu_2

Consolidated Valuation and Qualifying Accounts (Detail) - SEC Schedule, 12-09, Allowance, Credit Loss [Member] - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period		$ 15,960	$ 11,979	$ 12,309
Additions charged to expense or as reductions to revenue	[1]	276,988	65,649	65,142
Deductions	[2]	(189,513)	(61,668)	(65,472)
Balance at end of period		$ 103,435	$ 15,960	$ 11,979
[1]	Primarily represents charges for contract rebate allowances recorded as reductions to revenue. Additions to allowance for doubtful accounts are recorded to sales and marketing expense.
[2]	The deductions represent actual charges against the accrual described above.